Botulinum neurotoxins cleaving non-neuronal SNARE

By modifying the amino acid sequence of BoNT/AL chain protease, its ability to cleave non-neuronal SNARE proteins was improved, overcoming the limitations of existing technologies for application in non-neuronal systems and achieving effective inhibition of secretion by non-neuronal cells.

CN119020332APending Publication Date: 2024-11-26IPSEN BIOPHARM LTD
View PDF 16 Cites 0 Cited by

Patent Information

Application Number
CN202411159184.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2018-01-29
Filing Date
2019-01-29
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

Existing botulinum neurotoxins have the ability to specifically cleave neuronal SNARE proteins, but their cleavage effect on non-neuronal SNARE proteins is limited, restricting their therapeutic application in non-neuronal systems.

Method used

By modifying the amino acid sequence of botulinum neurotoxin A (BoNT/A) light chain protease, especially by substituting amino acids within the binding bag, its ability to cleave non-neuronal SNARE proteins (such as hSNAP-23) is enhanced.

Benefits of technology

The BoNT/AL chain protease enhanced the cleavage efficiency of hSNAP-23, achieving effective inhibition of secretion by non-neuronal cells and expanding its therapeutic potential in non-neuronal systems.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005005949700000431
    Figure BDA0005005949700000431
  • Figure HDA0005005949710000011
    Figure HDA0005005949710000011
  • Figure HDA0005005949710000021
    Figure HDA0005005949710000021
Patent Text Reader

Abstract

The present invention provides a modified Botulinum Neurotoxin A (BoNT / A) L-chain protease showing an enhanced cleavage of human SNAP-23 (hSNAP-23) relative to an unmodified (wild type) BoNT / A L-chain protease, and its use in cleavage of hSNAP-23.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application of Chinese patent application 201980006010.7. The filing date of the original application is January 29, 2019, and the name of the invention is “Botulinum neurotoxin that cuts non-neuronal SNAREs”.

[0002] introduce

[0003] The present invention relates to modified botulinum neurotoxin proteases having the ability to cleave non-neuronal SNARE proteins, and their use in inhibiting undesired secretion from mammalian cells by cleaving non-neuronal SNARE proteins in the mammalian cells.

[0004] Toxins generally fall into one of two categories, cytotoxic toxins that kill their natural target cells (e.g., plant toxins such as ricin) and non-cytotoxic toxins that do not kill their natural target cells (e.g., botulinum neurotoxin). Non-cytotoxic toxins exert their effects on target cells by inhibiting cellular processes other than protein synthesis.

[0005] Botulinum neurotoxin proteases act by proteolytically cleaving intracellular transporters called SNARE proteins (e.g., SNAP-25, VAMP, or syntaxin). The acronym SNARE is derived from the term soluble NSF attachment protein receptor ( S oluble N SF A tachment protein Re ceptor), where NSF refers to N-ethylmaleimide sensitive factor ( N -ethylmaleimide- S ensitive F SNARE proteins are a large superfamily of proteins. An important function of SNARE proteins is to mediate the exocytosis of neurotransmitter molecules to postsynaptic junctions. SNARE proteins are therefore essential for the secretion of molecules from cells via vesicular transport.

[0006] Clostridium botulinum produces seven (A to G) different neurotoxins (BoNTs) that are serologically distinguished by the lack of cross-serotype neutralization by antisera. BoNTs elicit neuron-specific flaccid paralysis by targeting neurons and cleaving neuron-specific SNARE proteins.

[0007] BoNT has a 150 kDa polypeptide chain consisting of a 100 kDa heavy chain and a 50 kDa light chain linked by disulfide bonds. BoNT is organized into three functional domains: an N-terminal proteolytic light chain (L chain) and a C-terminal heavy chain (H chain), the latter consisting of a translocation domain (H N ) and the C-terminal neuron binding domain (H C ) composition. The toxic effect (neurotoxicity) of BoNT follows a three-step mechanism of action. The first step, H C Some of them bind to cholinergic neurons and are internalized through receptor-mediated endocytosis. N Part of it causes the L chain to translocate across the endosomal membrane and enter the cytosol of the nerve cell. In the third step, the L chain binds to and cleaves the neuronal SNARE protein in the cytosol, thereby inhibiting the release of neurotransmitters from the nerve cell, leading to nerve cell poisoning.

[0008] The seven BoNT serotypes cleave specific residues on one of three SNARE proteins:

[0009] Serotypes B, D, F, and G cleave VAMP-2;

[0010] Serotypes A and E cleave SNAP-25; and

[0011] Serotype C cleaves SNAP-25 and syntaxin Ia.

[0012] While native BoNTs are able to target and cleave neuronal SNARE isoforms such as VAMP-2, SNAP-25, and syntaxin 1a, the proteases have little or no cleavage on most non-neuronal SNARE proteins. This neuronal SNARE substrate specificity is consistent with, and is understood to be a reflection of, the native neuronal cell binding specificity exhibited by BoNTs. For example, BoNT / A cleaves human SNAP-25, but not human non-neuronal isoforms.

[0013] BoNT / A was approved by the FDA as early as 1989 for the treatment of strabismus, blepharospasm, and hemifacial spasm, and then for cervical dystonia, cosmetic uses, glabellar lines, and axillary hyperhidrosis. The efficacy of BoNT / A in dystonia and other disorders associated with involuntary skeletal muscle activity and its favorable safety profile have inspired empirical / off-label use in a variety of secretory and pain and cosmetic disorders.

[0014] Clinical applications of BoNTs have focused on targeting disorders associated with neuromuscular activity. Recently, pioneering research led by Syntaxin Ltd has allowed the design of retargeted BoNTs that bind to unique subsets of neurons (e.g. nociceptive afferents - see WO96 / 33273, incorporated herein in its entirety) and / or bind to non-neuronal cells (e.g. airway epithelial cells - see WO00 / 10598, incorporated herein in its entirety). This technology, called targeted secretion inhibitor (TSI) technology, involves replacing the native BoNT binding domain with a different targeting moiety (e.g. growth factor or other signaling molecule), opening the door to new BoNT-based therapeutics and treatments.

[0015] However, the selective cleavage of neuron-specific SNARE proteins by BoNTs has limited the development of new therapeutics in these non-neuronal systems. Neuronal and non-neuronal SNARE proteins are thought to be equally important for intracellular vesicle fusion and, therefore, for secretion of molecules from cells via vesicular trafficking. Therefore, inactivation of neuronal SNARE protein-driven secretion with conventional BoNT-based therapeutics will not involve any corresponding non-neuronal SNARE-driven cellular secretion.

[0016] Therefore, there exists a need for engineered BoNT L chain proteases that efficiently cleave non-neuronal SNARE proteins.

[0017] The present invention solves one or more of the above problems by providing engineered BoNT / AL chain proteases that cleave SNARE protein isoforms expressed primarily in non-neuronal cells, namely human SNAP-23 (hSNAP-23). ​​The present invention thus provides a new class of non-cytotoxic therapeutic agents. DETAILED DESCRIPTION OF THE INVENTION

[0019] Unless otherwise defined herein, scientific and technical terms used in conjunction with the present invention have the meanings commonly understood by those of ordinary skill in the art. In addition, unless the context requires otherwise, the nomenclature and cell and tissue culture techniques used herein are those well known and commonly used in the art.

[0020] However, for various terms used throughout this specification, the following definitions apply with particular particularity.

[0021] Unless the context indicates otherwise, the singular terms "a", "an" or "the" include plural references such as "one or more", or "at least one".

[0022] The term "protease" refers herein to an enzyme that is capable of hydrolytically cleaving proteins and / or peptides. In the context of the present invention, the protease is more specifically a botulinum neurotoxin (BoNT) light chain (L-chain) protease, i.e. a protease derived from a botulinum neurotoxin, in particular from a botulinum neurotoxin A (BoNT / A) (also described as a proteolytic domain). As is well known to skilled practitioners, the light chain of a botulinum neurotoxin provides a protease function (also referred to as a non-cytotoxic protease function) and typically has a molecular weight of about 50 kDa. Such non-cytotoxic proteases typically act by proteolytically cleaving intracellular transporters known as SNARE proteins (e.g., SNAP-25, VAMP, or syntaxin) - see Gerald K (2002) "Cell and Molecular Biology" (4th edition) John Wiley & Sons, Inc. As further explained below, the naturally occurring (i.e., wild-type) BoNT / AL chain is more particularly capable of efficiently cleaving SNAP-25, but only weakly cleaving hSNAP-23. In contrast, the BoNT / AL chain protease of the present invention, described in more detail below, differs from the naturally occurring BoNT / AL chain in that it has an improved ability to cleave hSNAP-23 and is referred to herein as a "modified BoNT / AL chain that cleaves hSNAP-23."

[0023] The ability to cleave hSNAP23 can be confirmed by conventional assays, such as the assay described below in Example 2. "Cleaving hSNAP23" more particularly refers herein to a modified BoNT / AL chain of the invention that exhibits improved hSNAP-23 cleavage relative to a wild-type BoNT / AL chain (SEQ ID NO: 1). Any simple comparative assay can be utilized, such as the hSNAP-23 assay listed in Example 2. The wild-type BoNT / AL chain is only capable of weak (i.e., background) hSNAP-23 cleavage.

[0024] Thus, the modified BoNT / AL chains of the invention exhibit one or more (preferably both) of the following:

[0025] a) greater than 0.2% (e.g., greater than 0.5%, preferably greater than 1%, more preferably greater than 5%) hSNAP-23 cleavage in a cell-free assay (1 micromolar modified BoNT / AL chain; 20 micromolar hSNAP-23; preferably incubated at about 37° C. for about 1 hour) - see Example 2, FIG1 ; and / or

[0026] b) a Km of less than 225 (e.g., less than 200, preferably less than 150) micromolar in a cell-free assay (1 micromolar modified BoNT / AL chain; 20 micromolar hSNAP-23; preferably incubated at about 37° C. for about 1 hour) - see Example 2, FIG1 ; and / or

[0027] c) Kcat (1 / min) is less than 0.2 (e.g., less than 0.18, preferably less than 0.1) in a cell-free assay (1 micromolar modified BoNT / AL chain; 20 micromolar hSNAP-23; preferably incubated at about 37° C. for about 1 hour) - see Example 2, FIG1 .

[0028] The modified BoNT / AL chain proteases of the present invention may optionally cleave not only hSNAP-23, but also SNAP-25. Cleavage of SNAP-25 can be confirmed by conventional assays, such as the assay described in Example 3 below. According to this optional embodiment, "cleavage of SNAP-25" herein means that the modified BoNT / AL chain of the present invention preferably exhibits at least 0.5%, at least 1%, at least 2%, preferably at least 3%, and also preferably at least 10% SNAP-25 cleavage relative to the wild-type BoNT / AL chain (SEQ ID NO: 1). Any simple comparative assay can be utilized, such as the SNAP-25 assay listed in Example 3.

[0029] In preferred embodiments, the modified BoNT / AL chain proteases of the invention cleave hSNAP-23 but not SNAP-25, such as hSNAP-25.

[0030] The term "SNAP-23" (synaptosome-associated protein 23) herein refers to a SNARE protein that is able to bind to a variety of other SNARE proteins in cells, preferably in non-neuronal cells, and form high-affinity complexes with these proteins, thereby regulating intracellular cell membrane fusion in the cell. "hSNAP-23" more particularly refers to human SNAP-23, preferably to a protein of sequence SEQ ID NO: 2.

[0031] The term "SNAP-25" (synaptosome-associated protein 25) herein refers to a SNARE protein that is able to bind to a variety of other SNARE proteins in cells, preferably in neuronal cells, and form a high-affinity complex, thereby regulating intracellular cell membrane fusion in the cell. "hSNAP-25" more particularly refers to human SNAP-25, preferably to a protein of sequence SEQ ID NO: 3.

[0032] The terms "modification," "alteration," or "mutation" are used interchangeably herein and refer to a change in an amino acid sequence compared to the amino acid sequence of a reference protein, i.e., herein relative to a wild-type BoNT / AL chain (SEQ ID NO: 1). The amino acid sequence recited herein as SEQ ID NO: 1 is 438 amino acid residues in length, ending with K438. It should be understood that K438 is the first lysine amino acid residue of the activation loop and most likely represents the C-terminus of the L chain after proteolytic cleavage of the activation loop. Thus, SEQ ID NO: 1 represents a wild-type BoNT / AL chain in (native) activated form. In this regard, prior to proteolytic activation, a wild-type BoNT / AL chain is typically ˜448 amino acid residues in length, including a short C-terminal extension of activation loop amino acid residues.

[0033] As further explained below, the present invention discloses the identity of key amino acid positions within the wild-type BoNT / AL chain that need to be rationally changed to different amino acid residues in order for the BoNT / AL chain to be capable of hSNAP-23 cleavage. In this regard, the introduction of amino acid changes (i.e., mutations) can be achieved by amino acid insertion, deletion or substitution, preferably by amino acid substitution. Methods allowing the introduction of such mutations are known to those skilled in the art. For example, it is possible to introduce mutations in a nucleotide sequence encoding a reference protein by random or directed mutagenesis, by PCR using degenerate primers. This technique is described in particular by Sambrook et al. in "Molecular Cloning: A laboratory Manual", 4th edition, Cold Spring Harbor Laboratory Press, (2012, and updated versions after 2014) and Ausubel et al. in "Current Protocols in Molecular Biology", John Wiley & Sons (2012).

[0034] The amino acid changes occur within one or more L chain "binding pockets" relative to the wild-type BoNT / AL chain (SEQ ID NO: 1). A "binding pocket" herein refers to a region of a BoNT / AL chain that contains one or more amino acids that serve as contact points for binding to the corresponding binding site of hSNAP-23 (e.g., via hydrogen bonds, salt bridges, and / or hydrophobic contacts), and / or that provides space for accommodating other substrate amino acid residues that are capable of binding to hSNAP-23 (e.g., via modification, such as by substitution). The term "binding" as used herein means "suitable for binding" and forms part of the applicant's principles for the present invention - the principles do not constitute an essential feature of the present invention. For example, the BoNT / AL chain protease binding pocket defined as amino acid residues E148, T307, A308, and Y312 of SEQ ID NO: 1 refers to the region of the BoNT / AL chain protease comprising amino acids E148, T307, A308, and / or Y312, and / or mutants thereof described herein, which Applicants believe bind synergistically to a predicted binding site on hSNAP-23 (e.g., binds to the P182 / D178 binding site of hSNAP-23).

[0035] The term "binding site" herein refers to a region of hSNAP-23 that comprises one or more amino acids that can be bound by the corresponding BoNT / AL chain binding pocket. For example, the "P182 / D178" binding site of hSNAP-23 comprises amino acids P182 and / or D178 of hSNAP-23. The term "binding site" as used herein refers only to a "predicted binding site" (as predicted by the applicant) and forms part of the applicant's principles for the present invention - the principles do not constitute an essential feature of the present invention.

[0036] "Sequence identity" between amino acid or nucleic acid sequences can be determined by comparing positions in each sequence, which sequences can be aligned for comparison purposes. When a position in the compared sequences is occupied by the same nucleotide or amino acid, then the sequences are identical at that position. The degree of identity between amino acid sequences is a function of the number of identical amino acid sequences shared by the sequences. The degree of sequence identity between nucleic acids is a function of the number of identical nucleotides shared by the sequences at that position.

[0037] To determine the "percentage of sequence identity" between two amino acid sequences or two nucleic acid sequences, the sequences are aligned for optimal comparison. For example, a gap can be introduced into the sequence of a first amino acid sequence or a first nucleic acid sequence in order to optimally compare with a second amino acid sequence or a second nucleic acid sequence. The amino acid residues or nucleotides at the corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, the molecules are identical at that position.

[0038] The percentage (%) of identity between two sequences is a function of the number of identical positions shared by these sequences. Thus, the percentage of identity can be calculated by multiplying the number of identical positions by 100 divided by the length of the alignment region (overlapping positions) including gaps (internal gaps only, not gaps at the ends of the sequences).

[0039] In this comparison, the sequences can be of the same length, or can be of different lengths. The identity score counts only perfect matches, without taking into account how similar the amino acids are to each other.

[0040] Optimal alignment of sequences may preferably be performed herein by a global homology alignment algorithm, which can be used to align sequences of equal or similar length, such as the algorithm described by Needleman and Wunsch (Journal of Molecular Biology; 1970, 48(3): 443-53), by a computerized implementation of this algorithm (e.g. using Alternatively, sequences of different lengths (e.g., the amino acid sequence of a light chain of the invention versus the entire amino acid sequence of a naturally occurring botulinum neurotoxin) may be aligned, and optimal alignment of the sequences may preferably be performed herein by a local homology alignment algorithm, such as that described by Smith and Waterson (Journal of Molecular Biology; 1981, 147: 195-197), by a computerized implementation of this algorithm (e.g., using Lasergene software), or by visual inspection. The best alignment produced by a variety of methods is selected (i.e., the one that produces the highest percent identity between the compared sequences). Examples of global and local homology alignment algorithms are well known to the skilled practitioner, and include, without limitation, ClustalV (local alignment), ClustalW (local alignment), and BLAST (local alignment).

[0041] A skilled practitioner can readily further appreciate that the present invention encompasses modified BoNT / AL chains that are substantially homologous and retain the ability to cleave hSNAP-23, i.e., functional variants or homologs. These functional variants or homologs can be characterized as having one or more amino acid mutations (e.g., amino acid deletions, additions, and / or substitutions) in addition to the mutations disclosed below for hSNAP-23 cleavage, and which do not significantly affect folding or protease activity, especially hSNAP-23 cleavage. For example, such mutations include, but are not limited to, conservative substitutions, small deletions (typically 1 to about 30 amino acids), small amino-terminal or carboxyl-terminal extensions (e.g., amino-terminal methionine residues), additions of small linker peptides of up to about 20-25 residues, or affinity tags.

[0042] Functional variants or homologues of the present invention preferably contain mutations of minor nature, such as conservative amino acid substitutions. Conservative amino acid substitutions are well known to skilled practitioners and include, but are not limited to:

[0043] Basic amino acids: arginine, lysine, histidine;

[0044] Acidic amino acids: glutamic acid, aspartic acid;

[0045] Polar amino acids: glutamine, asparagine;

[0046] Hydrophobic amino acids: leucine, isoleucine, valine, methionine;

[0047] Aromatic amino acids: phenylalanine, tryptophan, tyrosine;

[0048] Small amino acids: glycine, alanine, serine, threonine.

[0049] In addition to the 20 standard amino acids, non-standard amino acids (such as 4-hydroxyproline, 6-N-methyllysine, 2-aminoisobutyric acid, isovaline and α-methylserine) can also replace the amino acid residues of the polypeptides of the present invention. A limited number of non-conservative amino acids, amino acids not encoded by the genetic code and non-natural amino acids can replace the Clostridium polypeptide amino acid residues. The polypeptides of the present invention can also contain non-naturally occurring amino acid residues.

[0050] Non-naturally occurring amino acids include, but are not limited to, trans-3-methylproline, 2,4-methoxyproline, cis-4-hydroxyproline, trans-4-hydroxyproline, N-methylglycine, allo-threonine, methylthreonine, hydroxyethylcysteine, hydroxyethylhomocysteine, nitroglutamine, homoglutamine, piperidine carboxylic acid, tert-leucine, norvaline, 2-azaphenylalanine, 3-azaphenylalanine, 4-azaphenylalanine, and 4-fluorophenylalanine. Several methods are known in the art for incorporating non-naturally occurring amino acid residues into proteins.

[0051] Amino acid substitutions may include substitutions of amino acids having certain physicochemical properties (e.g., hydrophobicity) with amino acids having similar or alternative properties. Examples of such substitutions are listed below:

[0052] Acidic amino acids replace neutral polar amino acids;

[0053] Substitution of polar amino acids for nonpolar amino acids;

[0054] Substitution of nonpolar amino acids for nonpolar amino acids;

[0055] Nonpolar amino acids replace polar amino acids;

[0056] Polar amino acids replace basic amino acids;

[0057] Nonpolar amino acids replace acidic amino acids;

[0058] Non-polar amino acids replace polar amino acids.

[0059] Thus, the present invention encompasses L chains of all BoNT / A subtypes comprising one or more mutations described herein for cleavage of hSNAP-23, such as any of the BoNT / A1 to BoNT / A8 L chains. The BoNT / AL chain may also comprise additional mutations to provide non-native activation cleavage sites, such as cleavage sites for enterokinase (SEQ ID NO: 10), PreScission, Factor Xa, thrombin, TEV protease, and the like.

[0060] Additional definitions are provided throughout this specification.

[0061] The present invention can be described as follows.

[0062] In a first aspect, the present invention provides a modified botulinum neurotoxin A (BoNT / A) L chain protease that cleaves human SNAP-23 (hSNAP-23) and has a modified amino acid sequence relative to the wild-type BoNT / AL chain (SEQ ID NO: 1), comprising:

[0063] a) alteration of at least one amino acid residue within the first BoNT / AL chain protease binding pocket located at the P182 / D178 binding site for binding to hSNAP-23;

[0064] b) wherein the first BoNT / AL chain protease binding pocket is defined by amino acid residues E148, T307, A308, and Y312 of the wild-type BoNT / AL chain (SEQ ID NO: 1); and

[0065] c) wherein the at least one amino acid residue change comprises:

[0066] i. an amino acid residue selected from the group consisting of asparagine and tyrosine at the position on the modified L chain protease amino acid sequence corresponding to amino acid residue E148 of the wild-type BoNT / AL chain (SEQ ID NO: 1); and / or

[0067] ii. an amino acid residue selected from the group consisting of phenylalanine, isoleucine, and leucine at the position on the modified L chain protease amino acid sequence corresponding to amino acid residue T307 of the wild-type BoNT / AL chain (SEQ ID NO: 1); and / or

[0068] iii. an amino acid residue selected from the group consisting of proline, asparagine, threonine, and isoleucine at the position on the modified L chain protease amino acid sequence corresponding to amino acid residue A308 of the wild-type BoNT / AL chain (SEQ ID NO: 1); and / or

[0069] iv. an amino acid residue selected from the group consisting of lysine, valine, methionine, and leucine at the position on the modified L chain protease amino acid sequence corresponding to amino acid residue Y312 of the wild-type BoNT / AL chain (SEQ ID NO: 1).

[0070] Without wishing to be bound by any theory, applicants believe that the BoNT / AL chain binding pocket defined above and the recognition sequence on hSNAP-23 enable important enzyme-substrate binding.

[0071] Thus, the present invention is based on the surprising discovery (e.g., unexpected technical effect) that the claimed targeted amino acid substitutions allow for the generation of BoNT / AL chains that increase hSNAP-23 cleavage relative to wild-type BoNT / AL chains. The inventors have not only successfully identified the appropriate amino acid positions of the BoNT / AL chain that can be altered (e.g., substituted) to increase hSNAP-23 cleavage, but also identified the exact amino acid substitutions that provide this effect.

[0072] In a first aspect, the present invention provides a modified botulinum neurotoxin A (BoNT / A) L chain protease that cleaves human SNAP-23 (hSNAP-23) and has a modified amino acid sequence relative to the wild-type BoNT / AL chain (SEQ ID NO: 1), comprising:

[0073] a) alteration of at least one amino acid residue within the first BoNT / AL chain protease binding pocket located at the P182 / D178 binding site for binding to hSNAP-23;

[0074] b) wherein the first BoNT / AL chain protease binding pocket is defined as amino acid residue E148 of the wild-type BoNT / AL chain (SEQ ID NO: 1); and

[0075] c) wherein the at least one amino acid residue change comprises:

[0076] i. An amino acid residue selected from the group consisting of asparagine and tyrosine at the position on the modified L chain protease amino acid sequence corresponding to amino acid residue E148 of the wild-type BoNT / AL chain (SEQ ID NO: 1).

[0077] In one aspect, the present invention provides a modified botulinum neurotoxin A (BoNT / A) L chain protease that cleaves human SNAP-23 (hSNAP-23) and has a modified amino acid sequence relative to the wild-type BoNT / AL chain (SEQ ID NO: 1), comprising:

[0078] a) alteration of at least one amino acid residue within the first BoNT / AL chain protease binding pocket located at the P182 / D178 binding site for binding to hSNAP-23;

[0079] b) wherein the first BoNT / AL chain protease binding pocket is defined by amino acid residues E148, T307, A308, and Y312 of the wild-type BoNT / AL chain (SEQ ID NO: 1); and

[0080] c) wherein the at least one amino acid residue change comprises:

[0081] i. an amino acid residue selected from the group consisting of phenylalanine, isoleucine, and leucine at the position on the modified L chain protease amino acid sequence corresponding to amino acid residue T307 of the wild-type BoNT / AL chain (SEQ ID NO: 1); and / or

[0082] ii. an amino acid residue selected from the group consisting of proline, asparagine, threonine, and isoleucine at the position on the modified L chain protease amino acid sequence corresponding to amino acid residue A308 of the wild-type BoNT / AL chain (SEQ ID NO: 1); and / or

[0083] iii. an amino acid residue selected from the group consisting of lysine, valine, methionine, and leucine at the position on the modified L chain protease amino acid sequence corresponding to amino acid residue Y312 of the wild-type BoNT / AL chain (SEQ ID NO: 1).

[0084] A modified BoNT / AL chain can comprise one amino acid substitution (relative to wild-type SEQ ID NO: 1). A modified BoNT / AL chain can comprise two amino acid substitutions (relative to wild-type WT SEQ ID NO: 1). A modified BoNT / AL chain can comprise three amino acid substitutions (relative to wild-type SEQ ID NO: 1). A modified BoNT / AL chain can comprise four amino acid substitutions (relative to wild-type SEQ ID NO: 1).

[0085] Modified BoNT / AL chains of the invention comprising binding pocket mutations for the P182 / D178 binding site on hSNAP-23 generally exhibit at least 1.15-fold increased hSNAP-23 cleavage (relative to wild-type BoNT / AL chain) - see Figure 1A Examples of such modified BoNT / AL chains (referred to by amino acid substitution relative to the corresponding wild-type BoNT / AL chain SEQ ID NO: 1) include:

[0086] A modified BoNT / AL chain containing the substitution E148Y or E148N;

[0087] a modified BoNT / AL chain containing substitutions T307I, A308P, and Y312V;

[0088] a modified BoNT / AL chain containing substitutions T307F, A308N, and Y312L;

[0089] a modified BoNT / AL chain containing substitutions E148N, T307I and A308P, Y312V;

[0090] a modified BoNT / AL chain containing substitutions E148Y, T307F, A308N, and Y312L;

[0091] a modified BoNT / AL chain containing substitutions E148Y, T307I, A308P, and Y312V;

[0092] a modified BoNT / AL chain containing substitutions E148Y, T307L, A308T, and Y312M;

[0093] Modified BoNT / AL chains containing substitutions E148Y, T307L, A308I, and Y312M.

[0094] Modified BoNT / AL chains of the invention comprising binding pocket mutations for the P182 / D178 binding site on hSNAP-23 exhibit at least 1.35-fold increased hSNAP-23 cleavage (relative to wild-type BoNT / AL chain) - see Figure 1A Examples of such modified BoNT / AL chains (referred to by amino acid substitution relative to the corresponding wild-type BoNT / AL chain SEQ ID NO: 1) include:

[0095] A modified BoNT / AL chain containing the substitution E148Y or E148N;

[0096] a modified BoNT / AL chain containing substitutions T307I, A308P, and Y312V;

[0097] a modified BoNT / AL chain containing substitutions T307F, A308N, and Y312L;

[0098] a modified BoNT / AL chain containing substitutions E148N, T307I, A308P, and Y312V;

[0099] a modified BoNT / AL chain containing substitutions E148Y, T307F, A308N, and Y312L;

[0100] a modified BoNT / AL chain containing substitutions E148Y, T307I, A308P, and Y312V;

[0101] a modified BoNT / AL chain containing substitutions E148Y, T307L, A308T, and Y312M;

[0102] Modified BoNT / AL chains containing substitutions E148Y, T307L, A308I, and Y312M.

[0103] Modified BoNT / AL chains of the invention comprising binding pocket mutations for the P182 / D178 binding site on hSNAP-23 exhibit at least 1.7-fold increased hSNAP-23 cleavage (relative to wild-type BoNT / AL chain) - see Figure 1A Examples of such modified BoNT / AL chains (referred to by amino acid substitution relative to the corresponding wild-type BoNT / AL chain SEQ ID NO: 1) include:

[0104] A modified BoNT / AL chain containing the substitution E148Y;

[0105] A modified BoNT / AL chain containing the substitution T307F;

[0106] a modified BoNT / AL chain containing the substitution T307I;

[0107] A modified BoNT / AL chain containing the substitution Y312K;

[0108] A modified BoNT / AL chain containing substitutions Y312K, E148Y;

[0109] a modified BoNT / AL chain containing substitutions T307I, A308P, and Y312V;

[0110] a modified BoNT / AL chain containing substitutions E148N, T307I, A308P, and Y312V;

[0111] a modified BoNT / AL chain containing substitutions E148Y, T307F, A308N, and Y312L;

[0112] Modified BoNT / AL chain containing substitutions E148Y, T307L, A308T, and Y312M.

[0113] Modified BoNT / AL chains of the invention comprising binding pocket mutations for the P182 / D178 binding site on hSNAP-23 can exhibit at least a 2.0-fold increase in hSNAP-23 cleavage (relative to wild-type BoNT / AL chain) - see Figure 1A Examples of such modified BoNT / AL chains (referred to by amino acid substitution relative to the corresponding wild-type BoNT / AL chain SEQ ID NO: 1) include:

[0114] A modified BoNT / AL chain containing the substitution E148Y;

[0115] a modified BoNT / AL chain containing substitutions E148N, T307I, A308P, and Y312V;

[0116] a modified BoNT / AL chain containing substitutions E148Y, T307F, A308N, and Y312L;

[0117] Modified BoNT / AL chain containing substitutions E148Y, T307L, A308T, and Y312M.

[0118] Modified BoNT / AL chains of the invention comprising binding pocket mutations for the P182 / D178 binding site on hSNAP-23 can exhibit at least a 4.0-fold increase in hSNAP-23 cleavage (relative to wild-type BoNT / AL chain) - see Figure 1A Examples of such modified BoNT / AL chains (referred to by amino acid substitution relative to the corresponding wild-type BoNT / AL chain SEQ ID NO: 1) include:

[0119] A modified BoNT / AL chain containing the substitution E148Y;

[0120] a modified BoNT / AL chain containing substitutions E148N, T307I, A308P, and Y312V;

[0121] a modified BoNT / AL chain containing substitutions E148Y, T307F, A308N, and Y312L;

[0122] Modified BoNT / AL chain containing substitutions E148Y, T307L, A308T, and Y312M.

[0123] In another embodiment, a modified BoNT / AL chain of the invention comprising a binding pocket mutation for the P182 / D178 binding site on hSNAP-23 can exhibit at least 6.0-fold, preferably at least 7.0-fold, more preferably at least 8.0-fold increased hSNAP-23 cleavage (relative to a wild-type BoNT / AL chain) - see Figure 1A Examples of such modified BoNT / AL chains (referred to by amino acid substitution relative to the corresponding wild-type BoNT / AL chain SEQ ID NO: 1) include:

[0124] Modified BoNT / AL chains containing the substitution E148Y.

[0125] Modified BoNT / AL chains of the invention comprising binding pocket mutations for the P182 / D178 binding site on hSNAP-23 generally exhibit greater than 1.5% hSNAP-23 cleavage (% of 1 micromolar modified BoNT / AL chain, 20 micromolar hSNAP-23, preferably incubated at about 37°C for about 1 hour) - see Figure 1A Column 2 in. For reference, a wild-type BoNT / AL chain (e.g., SEQ ID NO: 1) exhibits less than 0.5% hSNAP-23 cleavage (% of 1 micromolar modified BoNT / AL chain, 20 micromolar hSNAP-23, preferably incubated at about 37°C for about 1 hour). Examples of such modified L chains (referred to by amino acid substitution relative to the corresponding wild-type BoNT / AL chain SEQ ID NO: 1) include:

[0126] A modified BoNT / AL chain containing the substitution E148Y;

[0127] A modified BoNT / AL chain containing the substitution T307F;

[0128] a modified BoNT / AL chain containing the substitution T307I;

[0129] A modified BoNT / AL chain containing the substitution Y312K;

[0130] Modified BoNT / AL chains containing substitutions Y312K and E148Y.

[0131] In one embodiment, a modified BoNT / AL chain of the invention comprising a binding pocket mutation for the P182 / D178 binding site on hSNAP-23 generally exhibits greater than 2% hSNAP-23 cleavage (% of 1 micromolar modified BoNT / AL chain, 20 micromolar hSNAP-23, preferably incubated at about 37°C for about 1 hour) - see Figure 1A Such modified L chains (referred to by amino acid substitution relative to the corresponding wild-type BoNT / AL chain SEQ ID NO: 1) include:

[0132] A modified BoNT / AL chain containing the substitution E148Y;

[0133] a modified BoNT / AL chain containing the substitution T307I;

[0134] Modified BoNT / AL chain containing the substitution Y312K.

[0135] In another embodiment, a modified BoNT / AL chain of the invention comprising a binding pocket mutation for the P182 / D178 binding site on hSNAP-23 exhibits at least 9% increased hSNAP-23 cleavage (% of 1 micromolar modified BoNT / AL chain, 20 micromolar hSNAP-23, preferably incubated at about 37° C. for about 1 hour)—see Figure 1A Examples of such modified L chains (referred to by amino acid substitution relative to the corresponding wild-type BoNT / AL chain SEQ ID NO: 1) include:

[0136] Modified BoNT / AL chains containing the substitution E148Y.

[0137] Other examples of modified BoNT / AL chain mutants having binding pocket mutations for the P182 / D178 binding site on hSNAP-23 (referred to by amino acid substitution relative to the corresponding wild-type BoNT / AL chain SEQ ID NO: 1) include:

[0138] A modified BoNT / AL chain containing the substitution A308L;

[0139] A modified BoNT / AL chain containing the substitution A308V;

[0140] A modified BoNT / AL chain containing the substitution A308I;

[0141] A modified BoNT / AL chain containing the substitution A308P;

[0142] A modified BoNT / AL chain containing the substitution A308N;

[0143] A modified BoNT / AL chain containing the substitution A308T;

[0144] A modified BoNT / AL chain containing the substitution Y312V;

[0145] A modified BoNT / AL chain containing the substitution Y312M;

[0146] Modified BoNT / AL chain containing the substitution Y312L.

[0147] The modified BoNT / AL chains of the present invention having binding pocket mutations for the P182 / D178 binding site on hSNAP-23 can comprise one or more amino acid residue changes as defined above relative to the wild-type BoNT / AL chain. By way of example, the modified BoNT / AL chains of the present invention can have a single amino acid residue mutation (within the binding pocket for the P182 / D178 binding site on hSNAP-23 defined above), such as a mutation to amino acid residue E148 corresponding to the wild-type BoNT / AL chain (SEQ ID NO: 1). Similarly, the modified BoNT / AL chains of the present invention can have more than one amino acid residue mutation (within the binding pocket for the P182 / D178 binding site on hSNAP-23 defined above), such as a mutation to amino acid residues T307, A308, and Y312 corresponding to the wild-type BoNT / AL chain (SEQ ID NO: 1).

[0148] In a preferred embodiment, a modified BoNT / AL chain of the invention having one or more binding pocket mutations for the P182 / D178 binding site on hSNAP-23 further comprises one or more mutations within one or more different BoNT / AL chain binding pockets for hSNAP-23 described further below.

[0149] The one or more different BoNT / AL chain protease binding pockets for hSNAP-23 include: a second BoNT / AL chain protease binding pocket for binding to the D189 / D192 binding site of hSNAP-23; a third BoNT / AL chain protease binding pocket for binding to the I198 binding site of hSNAP-23; a fourth BoNT / AL chain protease binding pocket for binding to the K185 binding site of hSNAP-23; a fifth BoNT / AL chain protease binding pocket for binding to the R186 binding site of hSNAP-23; a sixth BoNT / AL chain protease binding pocket for binding to the K206 binding site of hSNAP-23; a seventh BoNT / AL chain protease binding pocket for binding to the D210 binding site of hSNAP-23; and an eighth BoNT / AL chain protease binding pocket for binding to the D168 binding site of hSNAP-23.

[0150] Alternatively, according to various features of the present invention, the modified BoNT / AL chain may comprise one or more mutations within one or more BoNT / AL chain binding pockets outside of the binding pocket for the P182 / D178 binding site of hSNAP23 defined above.

[0151] The BoNT / AL chain binding pocket for hSNAP-23 and the corresponding mutations of interest are described in further detail below.

[0152] Thus, as another or alternative technical feature, the present invention includes a BoNT / AL chain mutant comprising one or more mutations within the BoNT / AL chain binding pocket as defined herein. As an example, a modified BoNT / AL chain of the present invention that cleaves human SNAP-23 (hSNAP-23) has a modified amino acid sequence relative to the wild-type BoNT / AL chain (SEQ ID NO: 1), comprising:

[0153] a) changes in amino acid residues located within the fifth BoNT / AL chain protease binding pocket of the R186 binding site for binding to hSNAP-23;

[0154] b) wherein the fifth BoNT / AL chain protease binding pocket is defined as amino acid residue S143 of the wild-type BoNT / AL chain (SEQ ID NO: 1); and

[0155] c) wherein the amino acid residue changes comprise:

[0156] i. An amino acid residue selected from the group consisting of glutamine, glutamic acid, and aspartic acid at the position on the modified L chain protease amino acid sequence corresponding to amino acid residue S143 of the wild-type BoNT / AL chain (SEQ ID NO: 1).

[0157] Without wishing to be bound by any theory, Applicants believe that the BoNT / AL chain binding pocket defined above provides a stabilizing salt bridge between R186 on hSNAP-23 and S143 on BoNT / A.

[0158] Modified BoNT / AL chains of the invention comprising binding pocket mutations for the R186 binding site on hSNAP-23 generally exhibit a K of 0.1 for hSNAP-23. M Less than 100 micromolar, for example less than 95 micromolar - see Figure 1A For reference, the wild-type BoNT / AL chain (e.g., SEQ ID NO: 1) exhibits a K of 1.0 for hSNAP-23. M Greater than 150 micromolar, such as greater than 200 micromolar. Examples of such modified BoNT / AL chains (referred to by amino acid substitution relative to the corresponding wild-type BoNT / AL chain SEQ ID NO: 1) include:

[0159] A modified BoNT / AL chain containing the substitution V304D;

[0160] A modified BoNT / AL chain containing the substitution V304E;

[0161] A modified BoNT / AL chain containing the substitution G305D;

[0162] A modified BoNT / AL chain containing the substitution G305E;

[0163] A modified BoNT / AL chain containing the substitution S143D;

[0164] A modified BoNT / AL chain containing the substitution S143E;

[0165] A modified BoNT / AL chain containing the substitution S143Q;

[0166] Modified BoNT / AL chain containing the substitution K166F.

[0167] In preferred embodiments, the modified BoNT / AL chains of the invention having a binding pocket mutation for the R186 binding site on hSNAP-23 may further comprise one or more mutations within one or more of the different BoNT / AL chain binding pockets described herein (e.g., within the binding pocket for the P182 / D178 binding site on hSNAP-23 defined above). Such mutants generally exhibit at least a 0.5-fold decrease in hSNAP-23 cleavage relative to the E148Y modified BoNT / AL chain, or in other words at least a 4.0-fold increase in hSNAP-23 cleavage relative to the wild-type BoNT / AL chain - see Figure 1B or at least 5% hSNAP-23 cleavage (% of 1 micromolar modified BoNT / AL chain, 20 micromolar hSNAP-23, preferably incubated at about 37°C for about 1 hour) - see Figure 1B Examples of such modified BoNT / AL chains (referred to by amino acid substitution relative to the corresponding wild-type BoNT / AL chain SEQ ID NO: 1) include:

[0168] A modified BoNT / AL chain containing substitutions E148Y and S143E;

[0169] A modified BoNT / AL chain containing substitutions E148Y and S143D;

[0170] Modified BoNT / AL chains containing substitutions E148Y and S143Q.

[0171] Thus, in one embodiment, a modified BoNT / AL chain protease is provided that cleaves human SNAP-23 (hSNAP-23) and has a modified amino acid sequence relative to the wild-type BoNT / AL chain (SEQ ID NO: 1), comprising:

[0172] a) altering an amino acid residue located within the first BoNT / AL chain protease binding pocket of the P182 / D178 binding site for binding hSNAP-23; wherein the first BoNT / AL chain protease binding pocket is defined as amino acid residue E148 of the wild-type BoNT / AL chain (SEQ ID NO: 1); and

[0173] b) altering an amino acid residue located within the fifth BoNT / AL chain protease binding pocket that is located within the R186 binding site for binding hSNAP-23; wherein the fifth BoNT / AL chain protease binding pocket is defined as amino acid residue S143 of the wild-type BoNT / AL chain (SEQ ID NO: 1); and

[0174] c) wherein the amino acid residue changes comprise:

[0175] i. an amino acid residue selected from tyrosine at the position on the modified L chain protease amino acid sequence corresponding to amino acid residue E148 of the wild-type BoNT / AL chain (SEQ ID NO: 1); and

[0176] ii. an amino acid residue selected from glutamic acid at the position on the modified L chain protease amino acid sequence corresponding to amino acid residue S143 of the wild-type BoNT / AL chain (SEQ ID NO: 1).

[0177] In another embodiment, a modified BoNT / AL chain protease is provided that cleaves human SNAP-23 (hSNAP-23) and has a modified amino acid sequence relative to the wild-type BoNT / AL chain (SEQ ID NO: 1), comprising:

[0178] a) altering an amino acid residue located within the first BoNT / AL chain protease binding pocket of the P182 / D178 binding site for binding hSNAP-23; wherein the first BoNT / AL chain protease binding pocket is defined as amino acid residue E148 of the wild-type BoNT / AL chain (SEQ ID NO: 1); and

[0179] b) altering an amino acid residue located within the fifth BoNT / AL chain protease binding pocket that is located within the R186 binding site for binding hSNAP-23; wherein the fifth BoNT / AL chain protease binding pocket is defined as amino acid residue S143 of the wild-type BoNT / AL chain (SEQ ID NO: 1); and

[0180] c) wherein the amino acid residue changes comprise:

[0181] i. an amino acid residue selected from tyrosine at the position on the modified L chain protease amino acid sequence corresponding to amino acid residue E148 of the wild-type BoNT / AL chain (SEQ ID NO: 1); and

[0182] ii. an amino acid residue selected from aspartic acid at the position on the modified L chain protease amino acid sequence corresponding to amino acid residue S143 of the wild-type BoNT / AL chain (SEQ ID NO: 1).

[0183] In another embodiment, the modified BoNT / AL chain of the invention having a binding pocket mutation for the R186 binding site on hSNAP-23 further comprises one or more mutations within one or more of the different BoNT / AL chain binding pockets described herein (e.g., within the binding pocket for the P182 / D178 binding site on hSNAP-23 defined above). Such mutants generally exhibit at least a 2.0-fold increase in hSNAP-23 cleavage (relative to the E148Y modified BoNT / AL chain) - see Figure 1B Examples of such modified BoNT / AL chains (referred to by amino acid substitution relative to the corresponding wild-type BoNT / AL chain SEQ ID NO: 1) include:

[0184] a modified BoNT / AL chain having substitutions E148Y and S143E;

[0185] Modified BoNT / AL chains with substitutions E148Y and S143D.

[0186] In another embodiment, the modified BoNT / AL chain of the invention having a binding pocket mutation for the R186 binding site on hSNAP-23 further comprises one or more mutations within one or more of the different BoNT / AL chain binding pockets described herein (e.g., within the binding pocket for the P182 / D178 binding site on hSNAP-23 defined above). Such mutants generally exhibit at least a 3.0-fold increase in hSNAP-23 cleavage (as a percentage relative to the E148Y modified BoNT / AL chain) - see Figure 1B Examples of such modified BoNT / AL chains (referred to by amino acid substitution relative to the corresponding wild-type BoNT / AL chain SEQ ID NO: 1) include:

[0187] Modified BoNT / AL chains containing substitutions E148Y, S143D.

[0188] As another or alternative technical feature, the present invention includes a BoNT / AL chain mutant comprising one or more mutations within the BoNT / AL chain binding pocket as defined herein. As an example, a modified BoNT / AL chain of the present invention that cleaves human SNAP-23 (hSNAP-23) has a modified amino acid sequence relative to a wild-type BoNT / AL chain (SEQ ID NO: 1), comprising:

[0189] a) alteration of at least one amino acid residue located within the fourth BoNT / AL chain protease binding pocket located within the K185 binding site for binding to hSNAP-23;

[0190] b) wherein the fourth BoNT / AL chain protease binding pocket is defined by amino acid residues V304 and G305 of the wild-type BoNT / AL chain (SEQ ID NO: 1); and

[0191] c) wherein the at least one amino acid residue change comprises:

[0192] i. an amino acid residue selected from glutamic acid and aspartic acid at the position on the modified L chain protease amino acid sequence corresponding to amino acid residue V304 of the wild-type BoNT / AL chain (SEQ ID NO: 1); and / or

[0193] ii. an amino acid residue selected from glutamic acid and aspartic acid at the position on the modified L chain protease amino acid sequence corresponding to amino acid residue G305 of the wild-type BoNT / AL chain (SEQ ID NO: 1).

[0194] Without wishing to be bound by any theory, Applicants believe that the BoNT / AL chain binding pocket defined above provides a stabilizing salt bridge between K185 on hSNAP-23 and BoNT / A.

[0195] Modified BoNT / AL chains of the invention comprising binding pocket mutations for the K185 binding site on hSNAP-23 generally exhibit a K of 1.0 for hSNAP-23. M Less than 100 micromolar—see Figure 1A For reference, the wild-type BoNT / AL chain (e.g., SEQ ID NO: 1) exhibits a K of 1.0 for hSNAP-23. M Greater than 150 micromolar, such as greater than 200 micromolar. Examples of such modified BoNT / AL chains (referred to by amino acid substitution relative to the corresponding wild-type BoNT / AL chain SEQ ID NO: 1) include:

[0196] A modified BoNT / AL chain containing the substitution V304D;

[0197] A modified BoNT / AL chain containing the substitution V304E;

[0198] A modified BoNT / AL chain containing the substitution G305D;

[0199] Modified BoNT / AL chain containing the substitution G305E.

[0200] The modified BoNT / AL chains of the present invention having binding pocket mutations for the K185 binding site on hSNAP-23 comprise one or more amino acid residue changes as defined above relative to the wild-type BoNT / AL chain. By way of illustration, the modified BoNT / AL chains of the present invention may have a single amino acid residue mutation (within the binding pocket for the K185 binding site on hSNAP-23 as defined above), such as a mutant of amino acid residue G305 corresponding to the wild-type BoNT / AL chain (SEQ ID NO: 1). Similarly, the modified BoNT / AL chains of the present invention may have more than one mutation, such as corresponding to amino acid residues V304 and G305 of the wild-type BoNT / AL chain (SEQ ID NO: 1) (within the binding pocket for the K185 binding site on hSNAP-23 as defined above).

[0201] In preferred embodiments, the modified BoNT / AL chains of the invention having a binding pocket mutation for the K185 binding site on hSNAP-23 may further comprise one or more mutations within one or more of the different BoNT / AL chain binding pockets described herein (e.g., within the binding pocket for the P182 / D178 binding site on hSNAP-23 defined above). Such mutants generally exhibit at least a 2.0-fold, preferably at least a 2.5-fold increase in hSNAP-23 cleavage (relative to the E148Y modified BoNT / AL chain) - see Figure 1B Examples of such modified BoNT / AL chains (referred to by amino acid substitution relative to the corresponding wild-type BoNT / AL chain SEQ ID NO: 1) include:

[0202] Modified BoNT / AL chain with substitutions E148Y and G305D.

[0203] Thus, in another embodiment, a modified BoNT / AL chain protease is provided that cleaves human SNAP-23 (hSNAP-23) and has a modified amino acid sequence relative to the wild-type BoNT / AL chain (SEQ ID NO: 1), comprising:

[0204] a) altering an amino acid residue located within the first BoNT / AL chain protease binding pocket of the P182 / D178 binding site for binding hSNAP-23; wherein the first BoNT / AL chain protease binding pocket is defined as amino acid residue E148 of the wild-type BoNT / AL chain (SEQ ID NO: 1); and

[0205] b) altering an amino acid residue located within the fourth BoNT / AL chain protease binding pocket that is located within the K185 binding site for binding hSNAP-23; wherein the fourth BoNT / AL chain protease binding pocket is defined as amino acid residue G305 of the wild-type BoNT / AL chain (SEQ ID NO: 1); and

[0206] c) wherein the amino acid residue changes comprise:

[0207] i. an amino acid residue selected from tyrosine at the position on the modified L chain protease amino acid sequence corresponding to amino acid residue E148 of the wild-type BoNT / AL chain (SEQ ID NO: 1); and

[0208] ii. an amino acid residue selected from aspartic acid at the position on the modified L chain protease amino acid sequence corresponding to amino acid residue G305 of the wild-type BoNT / AL chain (SEQ ID NO: 1).

[0209] In addition, as another technical feature or as an alternative technical feature, the present invention includes a BoNT / AL chain mutant comprising one or more mutations within the BoNT / AL chain binding pocket as defined herein. As an example, a modified BoNT / AL chain of the present invention that cleaves human SNAP-23 (hSNAP-23) has a modified amino acid sequence relative to the wild-type BoNT / AL chain (SEQ ID NO: 1), comprising:

[0210] a) changes in amino acid residues located within the second BoNT / AL chain protease binding pocket located at the D189 / D192 binding site for binding to hSNAP-23;

[0211] b) wherein the second BoNT / AL chain protease binding pocket is defined as amino acid residue Q29 of the wild-type BoNT / AL chain (SEQ ID NO: 1); and

[0212] c) wherein the amino acid residue changes comprise:

[0213] i. An amino acid residue alanine at the position of the modified L chain protease amino acid sequence corresponding to amino acid residue Q29 of the wild-type BoNT / AL chain (SEQ ID NO: 1).

[0214] Without wishing to be bound by any theory, Applicants believe that the BoNT / AL chain binding pocket defined above provides a stabilizing interaction between D189 / D192 on hSNAP-23 and amino acid 29 or nearby amino acids of BoNT / A.

[0215] Examples of such modified BoNT / AL chains (referred to by amino acid substitution relative to the corresponding wild-type BoNT / AL chain SEQ ID NO: 1) include:

[0216] Modified BoNT / AL chain with substitution Q29A.

[0217] In preferred embodiments, the modified BoNT / AL chains of the invention having binding pocket mutations for the D189 / D192 binding site on hSNAP-23 further comprise one or more mutations within one or more of the different BoNT / AL chain binding pockets described herein (e.g., within the binding pocket for the P182 / D178 binding site on hSNAP-23 defined above). Such mutants generally exhibit at least a 1.50-fold increase in hSNAP-23 cleavage (relative to the E148Y modified BoNT / AL chain) - see Figure 1B Column 1 provided for multiple binding pocket mutants in . Examples of such modified BoNT / AL chains (referred to by amino acid substitution relative to the corresponding wild-type BoNT / AL chain SEQ ID NO: 1) include:

[0218] Modified BoNT / AL chain with substitutions E148Y, Q29A.

[0219] Thus, in another embodiment, a modified BoNT / AL chain protease is provided that cleaves human SNAP-23 (hSNAP-23) and has a modified amino acid sequence relative to the wild-type BoNT / AL chain (SEQ ID NO: 1), comprising:

[0220] a) altering an amino acid residue located within the first BoNT / AL chain protease binding pocket of the P182 / D178 binding site for binding hSNAP-23; wherein the first BoNT / AL chain protease binding pocket is defined as amino acid residue E148 of the wild-type BoNT / AL chain (SEQ ID NO: 1); and

[0221] b) altering an amino acid residue located within the second BoNT / AL chain protease binding pocket located within the D189 / D192 binding site for binding hSNAP-23; wherein the second BoNT / AL chain protease binding pocket is defined as amino acid residue Q29 of the wild-type BoNT / AL chain (SEQ ID NO: 1); and

[0222] c) wherein the amino acid residue changes comprise:

[0223] i. an amino acid residue selected from tyrosine at the position on the modified L chain protease amino acid sequence corresponding to amino acid residue E148 of the wild-type BoNT / AL chain (SEQ ID NO: 1); and

[0224] ii. an amino acid residue selected from alanine at the position on the modified L chain protease amino acid sequence corresponding to amino acid residue Q29 of the wild-type BoNT / AL chain (SEQ ID NO: 1).

[0225] In another embodiment, a modified BoNT / AL chain of the invention having a binding pocket mutation for the D189 / D192 binding site on hSNAP-23 can further comprise one or more mutations within at least two different BoNT / AL chain binding pockets described herein (e.g., within a binding pocket for the P182 / D178 binding site on hSNAP-23, and within a binding pocket for the R186 binding site on hSNAP-23, both as defined above). Such mutants generally exhibit at least a 2.5-fold increase in hSNAP-23 cleavage (relative to the E148Y modified BoNT / AL chain) - see Figure 1B Examples of such modified BoNT / AL chains (referred to by amino acid substitution relative to the corresponding wild-type BoNT / AL chain SEQ ID NO: 1) include:

[0226] Modified BoNT / AL chains containing substitutions E148Y, Q29A, and S143D.

[0227] Thus, in another embodiment, a modified BoNT / AL chain protease is provided that cleaves human SNAP-23 (hSNAP-23) and has a modified amino acid sequence relative to the wild-type BoNT / AL chain (SEQ ID NO: 1), comprising:

[0228] a) altering an amino acid residue located within the first BoNT / AL chain protease binding pocket of the P182 / D178 binding site for binding hSNAP-23; wherein the first BoNT / AL chain protease binding pocket is defined as amino acid residue E148 of the wild-type BoNT / AL chain (SEQ ID NO: 1); and

[0229] b) altering an amino acid residue located within the second BoNT / AL chain protease binding pocket located within the D189 / D192 binding site for binding hSNAP-23; wherein the second BoNT / AL chain protease binding pocket is defined as amino acid residue Q29 of the wild-type BoNT / AL chain (SEQ ID NO: 1); and

[0230] c) altering an amino acid residue located within the fifth BoNT / AL chain protease binding pocket that is located within the R186 binding site for binding hSNAP-23; wherein the fifth BoNT / AL chain protease binding pocket is defined as amino acid residue S143 of the wild-type BoNT / AL chain (SEQ ID NO: 1); and

[0231] d) wherein the amino acid residue changes comprise:

[0232] i. an amino acid residue selected from tyrosine at the position on the modified L chain protease amino acid sequence corresponding to amino acid residue E148 of the wild-type BoNT / AL chain (SEQ ID NO: 1); and

[0233] ii. an amino acid residue selected from alanine at the position on the modified L chain protease amino acid sequence corresponding to amino acid residue Q29 of the wild-type BoNT / AL chain (SEQ ID NO: 1); and

[0234] iii. an amino acid residue selected from aspartic acid at the position on the modified L chain protease amino acid sequence corresponding to amino acid residue S143 of the wild-type BoNT / AL chain (SEQ ID NO: 1).

[0235] In another embodiment, the modified BoNT / AL chain of the invention having a binding pocket mutation for the D189 / D192 binding site on hSNAP-23 can further comprise one or more mutations within at least two different BoNT / AL chain binding pockets described herein (e.g., within the binding pocket for the P182 / D178 binding site on hSNAP-23, and within the binding pocket for the K185 binding site on hSNAP-23, as defined above). Such mutants generally exhibit at least a 3.0-fold, preferably at least a 3.4-fold increase in hSNAP-23 cleavage (relative to the E148Y modified BoNT / AL chain) - see Figure 1B Column 1 provided for multiple binding pocket mutants in . Examples of such modified BoNT / AL chains (referred to by amino acid substitution relative to the corresponding wild-type BoNT / AL chain SEQ ID NO: 1) include:

[0236] Modified BoNT / AL chains containing substitutions E148Y, Q29A, and G305D.

[0237] Thus, in another embodiment, a modified BoNT / AL chain protease is provided that cleaves human SNAP-23 (hSNAP-23) and has a modified amino acid sequence relative to the wild-type BoNT / AL chain (SEQ ID NO: 1), comprising:

[0238] a) altering an amino acid residue located within the first BoNT / AL chain protease binding pocket of the P182 / D178 binding site for binding hSNAP-23; wherein the first BoNT / AL chain protease binding pocket is defined as amino acid residue E148 of the wild-type BoNT / AL chain (SEQ ID NO: 1); and

[0239] b) altering an amino acid residue located within the second BoNT / AL chain protease binding pocket located within the D189 / D192 binding site for binding hSNAP-23; wherein the second BoNT / AL chain protease binding pocket is defined as amino acid residue Q29 of the wild-type BoNT / AL chain (SEQ ID NO: 1); and

[0240] c) altering an amino acid residue located within the fourth BoNT / AL chain protease binding pocket located within the K185 binding site for binding hSNAP-23; wherein the fourth BoNT / AL chain protease binding pocket is defined as amino acid residue G305 of the wild-type BoNT / AL chain (SEQ ID NO: 1); and

[0241] d) wherein the amino acid residue changes comprise:

[0242] i. an amino acid residue selected from tyrosine at the position on the modified L chain protease amino acid sequence corresponding to amino acid residue E148 of the wild-type BoNT / AL chain (SEQ ID NO: 1); and

[0243] ii. an amino acid residue selected from alanine at the position on the modified L chain protease amino acid sequence corresponding to amino acid residue Q29 of the wild-type BoNT / AL chain (SEQ ID NO: 1); and

[0244] iii. an amino acid residue selected from aspartic acid at the position on the modified L chain protease amino acid sequence corresponding to amino acid residue G305 of the wild-type BoNT / AL chain (SEQ ID NO: 1).

[0245] As another or alternative technical feature, the present invention includes a BoNT / AL chain mutant comprising one or more mutations within the BoNT / AL chain binding pocket as defined herein. As an example, a modified BoNT / AL chain of the present invention that cleaves human SNAP-23 (hSNAP-23) has a modified amino acid sequence relative to a wild-type BoNT / AL chain (SEQ ID NO: 1), comprising:

[0246] a) alteration of at least one amino acid residue located within the sixth BoNT / AL chain protease binding pocket located within the K206 binding site for binding to hSNAP-23;

[0247] b) wherein the sixth BoNT / AL chain protease binding pocket is defined by amino acid residues Y251, L256, V258, L367, and F369 of the wild-type BoNT / AL chain (SEQ ID NO: 1); and

[0248] c) wherein the at least one amino acid residue change comprises:

[0249] i. an amino acid residue selected from glutamic acid and aspartic acid at the position on the modified L chain protease amino acid sequence corresponding to amino acid residue Y251 of the wild-type BoNT / AL chain (SEQ ID NO: 1); and / or

[0250] ii. an amino acid residue selected from the group consisting of glutamic acid, aspartic acid, glutamine, glycine, alanine, and arginine at the position on the modified L chain protease amino acid sequence corresponding to amino acid residue L256 of the wild-type BoNT / AL chain (SEQ ID NO: 1); and / or

[0251] iii. an amino acid residue selected from the group consisting of serine, alanine, proline, leucine, and glutamic acid at the position on the modified L chain protease amino acid sequence corresponding to amino acid residue V258 of the wild-type BoNT / AL chain (SEQ ID NO: 1); and / or

[0252] iv. an amino acid residue selected from alanine and glycine at the position on the modified L chain protease amino acid sequence corresponding to amino acid residue L367 of the wild-type BoNT / AL chain (SEQ ID NO: 1); and / or

[0253] v. an amino acid residue selected from the group consisting of glycine, serine, and leucine at the position on the modified L chain protease amino acid sequence corresponding to amino acid residue F369 of the wild-type BoNT / AL chain (SEQ ID NO: 1).

[0254] As another or alternative technical feature, the present invention includes a BoNT / AL chain mutant comprising one or more mutations within the BoNT / AL chain binding pocket as defined herein. As an example, a modified BoNT / AL chain of the present invention that cleaves human SNAP-23 (hSNAP-23) has a modified amino acid sequence relative to a wild-type BoNT / AL chain (SEQ ID NO: 1), comprising:

[0255] a) alteration of at least one amino acid residue located within the sixth BoNT / AL chain protease binding pocket located within the K206 binding site for binding to hSNAP-23;

[0256] b) wherein the sixth BoNT / AL chain protease binding pocket is defined by amino acid residues Y251, L256, V258, L367, and F369 of the wild-type BoNT / AL chain (SEQ ID NO: 1);

[0257] c) wherein the at least one amino acid residue change comprises:

[0258] i. an amino acid residue selected from glutamic acid and aspartic acid at the position on the modified L chain protease amino acid sequence corresponding to amino acid residue Y251 of the wild-type BoNT / AL chain (SEQ ID NO: 1); and / or

[0259] ii. an amino acid residue selected from the group consisting of glutamine and arginine at the position on the modified L chain protease amino acid sequence corresponding to amino acid residue L256 of the wild-type BoNT / AL chain (SEQ ID NO: 1); and / or

[0260] iii. an amino acid residue selected from the group consisting of serine, leucine, and glutamic acid at the position on the modified L chain protease amino acid sequence corresponding to amino acid residue V258 of the wild-type BoNT / AL chain (SEQ ID NO: 1); and / or

[0261] iv. an amino acid residue selected from alanine and glycine at the position on the modified L chain protease amino acid sequence corresponding to amino acid residue L367 of the wild-type BoNT / AL chain (SEQ ID NO: 1); and / or

[0262] v. an amino acid residue selected from the group consisting of glycine, serine, and leucine at the position on the modified L chain protease amino acid sequence corresponding to amino acid residue F369 of the wild-type BoNT / AL chain (SEQ ID NO: 1).

[0263] Without wishing to be bound by any theory, applicants believe that the BoNT / AL chain binding pocket defined above and the (S3') position of the hSNAP-23 recognition sequence enable important enzyme-substrate binding.

[0264] As another or alternative technical feature, the present invention includes a BoNT / AL chain mutant comprising one or more mutations within the BoNT / AL chain binding pocket as defined herein. As an example, a modified BoNT / AL chain of the present invention that cleaves human SNAP-23 (hSNAP-23) has a modified amino acid sequence relative to a wild-type BoNT / AL chain (SEQ ID NO: 1), comprising:

[0265] a) alteration of at least one amino acid residue located within the sixth BoNT / AL chain protease binding pocket located within the K206 binding site for binding to hSNAP-23;

[0266] b) wherein the sixth BoNT / AL chain protease binding pocket is defined by amino acid residues Y251, L256, V258, L367, and F369 of the wild-type BoNT / AL chain (SEQ ID NO: 1); and

[0267] c) wherein the at least one amino acid residue change comprises:

[0268] i. an amino acid residue selected from glutamic acid and aspartic acid at the position on the modified L chain protease amino acid sequence corresponding to amino acid residue Y251 of the wild-type BoNT / AL chain (SEQ ID NO: 1); and / or

[0269] ii. an amino acid residue selected from the group consisting of glutamine and arginine at the position on the modified L chain protease amino acid sequence corresponding to amino acid residue L256 of the wild-type BoNT / AL chain (SEQ ID NO: 1); and / or

[0270] iii. an amino acid residue selected from the group consisting of serine, leucine, and glutamic acid at the position on the modified L chain protease amino acid sequence corresponding to amino acid residue V258 of the wild-type BoNT / AL chain (SEQ ID NO: 1); and / or

[0271] iv. an amino acid residue selected from alanine and glycine at the position on the modified L chain protease amino acid sequence corresponding to amino acid residue L367 of the wild-type BoNT / AL chain (SEQ ID NO: 1); and / or

[0272] v. an amino acid residue selected from the group consisting of glycine, serine, and leucine at the position on the modified L chain protease amino acid sequence corresponding to amino acid residue F369 of the wild-type BoNT / AL chain (SEQ ID NO: 1).

[0273] The modified BoNT / AL chains of the present invention having binding pocket mutations for the K206 binding site on hSNAP-23 comprise one or more amino acid residue changes as defined above relative to the wild-type BoNT / AL chain. By way of illustration, the modified BoNT / AL chains of the present invention may have a single amino acid residue mutation (within the binding pocket for the K206 binding site on hSNAP-23), such as a mutant corresponding to amino acid residue Y251 of the wild-type BoNT / AL chain (SEQ ID NO: 1). Similarly, the modified BoNT / AL chains of the present invention may comprise more than one mutation (within the binding pocket for the K206 binding site on hSNAP-23), such as a mutant corresponding to amino acid residues Y251 & L256 of the wild-type BoNT / AL chain (SEQ ID NO: 1).

[0274] Modified BoNT / AL chains of the invention comprising binding pocket mutations for the K206 binding site on hSNAP-23 generally exhibit greater than 1.5% hSNAP-23 cleavage (% of 1 micromolar modified BoNT / AL chain, 20 micromolar hSNAP-23, preferably incubated at about 37°C for about 1 hour) - see Figure 1A For reference, a wild-type BoNT / AL chain (e.g., SEQ ID NO: 1) exhibits less than 0.5% hSNAP-23 cleavage (% of 1 micromolar modified BoNT / AL chain, 20 micromolar hSNAP-23, preferably incubated at about 37°C for about 1 hour) - see Figure 1A Examples of such modified BoNT / AL chains (referred to by amino acid substitution relative to the corresponding wild-type BoNT / AL chain SEQ ID NO: 1) include:

[0275] A modified BoNT / AL chain containing the substitution Y251D;

[0276] A modified BoNT / AL chain containing the substitution Y251E;

[0277] Modified BoNT / AL chain containing the substitution L256D.

[0278] In one embodiment, a modified BoNT / AL chain of the invention exhibits at least 3% hSNAP-23 cleavage (% of 1 micromolar modified BoNT / AL chain, 20 micromolar hSNAP-23, preferably incubated at about 37°C for about 1 hour) - see Figure 1AExamples of such modified BoNT / AL chains (referred to by amino acid substitution relative to the corresponding wild-type BoNT / AL chain SEQ ID NO: 1) include:

[0279] Modified BoNT / AL chain containing the substitution Y251E.

[0280] Other examples of modified BoNT / AL chains with binding pocket mutations for K206 on hSNAP-23 (referred to by amino acid substitution relative to the corresponding wild-type BoNT / AL chain SEQ ID NO: 1) include:

[0281] A modified BoNT / AL chain containing the substitution V245D;

[0282] A modified BoNT / AL chain containing the substitution L256E;

[0283] A modified BoNT / AL chain containing the substitution L256G;

[0284] A modified BoNT / AL chain containing the substitution L256Q;

[0285] A modified BoNT / AL chain containing the substitution L256A;

[0286] A modified BoNT / AL chain containing the substitution V258A;

[0287] A modified BoNT / AL chain containing the substitution V258P;

[0288] A modified BoNT / AL chain containing the substitution V258L;

[0289] A modified BoNT / AL chain containing substitutions L256E and V258P;

[0290] A modified BoNT / AL chain containing substitutions L256Q and V258P;

[0291] A modified BoNT / AL chain containing substitutions L256A and V258L;

[0292] Modified BoNT / AL chains containing substitutions L256G and V258L.

[0293] In preferred embodiments, the modified BoNT / AL chains of the invention having binding pocket mutations for the K206 binding site on hSNAP-23 may further comprise one or more mutations within one or more of the different BoNT / AL chain binding pockets described herein (e.g., within the binding pocket for the P182 / D178 binding site on hSNAP-23 defined above). Such mutants generally exhibit at least a 0.5-fold decrease in hSNAP-23 cleavage relative to the E148Y modified BoNT / AL chain, or in other words at least a 4.0-fold increase in hSNAP-23 cleavage relative to the wild-type BoNT / AL chain - see Figure 1B or at least 5% hSNAP-23 cleavage (% of 1 micromolar modified BoNT / AL chain, 20 micromolar hSNAP-23, preferably incubated at about 37° C. for about 1 hour) - see Figure 1B Preferred examples of such modified BoNT / AL chains (referred to by amino acid substitution relative to the corresponding wild-type BoNT / AL chain SEQ ID NO: 1) include:

[0294] A modified BoNT / AL chain containing substitutions E148Y and Y251D;

[0295] A modified BoNT / AL chain containing substitutions E148Y and L256D;

[0296] Modified BoNT / AL chains containing substitutions E148Y and Y251E.

[0297] Thus, in another embodiment, a modified BoNT / AL chain protease is provided that cleaves human SNAP-23 (hSNAP-23) and has a modified amino acid sequence relative to the wild-type BoNT / AL chain (SEQ ID NO: 1), comprising:

[0298] a) altering an amino acid residue located within the first BoNT / AL chain protease binding pocket of the P182 / D178 binding site for binding hSNAP-23; wherein the first BoNT / AL chain protease binding pocket is defined as amino acid residue E148 of the wild-type BoNT / AL chain (SEQ ID NO: 1); and

[0299] b) altering an amino acid residue located within the fifth BoNT / AL chain protease binding pocket that is located within the K206 binding site for binding hSNAP-23; wherein the fifth BoNT / AL chain protease binding pocket is defined as amino acid residue Y251 of the wild-type BoNT / AL chain (SEQ ID NO: 1); and

[0300] c) wherein the amino acid residue changes comprise:

[0301] i. an amino acid residue selected from tyrosine at the position on the modified L chain protease amino acid sequence corresponding to amino acid residue E148 of the wild-type BoNT / AL chain (SEQ ID NO: 1); and

[0302] ii. an amino acid residue selected from aspartic acid at the position on the modified L chain protease amino acid sequence corresponding to amino acid residue Y251 of the wild-type BoNT / AL chain (SEQ ID NO: 1).

[0303] In another embodiment, a modified BoNT / AL chain of the invention having a binding pocket mutation for the K206 binding site on hSNAP-23 can further comprise one or more mutations within at least three different BoNT / AL chain binding pockets described herein (e.g., within a binding pocket for the P182 / D178 binding site on hSNAP-23, within a binding pocket for the R186 binding site on hSNAP-23, and within a binding pocket for the D189 / D192 binding site, as defined above). Such mutants generally exhibit at least a 1.3-fold increase in hSNAP-23 cleavage (relative to the E148Y modified BoNT / AL chain) - see Figure 1B Column 1 provided for multiple binding pocket mutants in . Examples of such modified BoNT / AL chains (referred to by amino acid substitution relative to the corresponding wild-type BoNT / AL chain SEQ ID NO: 1) include:

[0304] Modified BoNT / AL chains containing substitutions E148Y, S143D, Q29A, and Y251E.

[0305] Thus, in another embodiment, a modified BoNT / AL chain protease is provided that cleaves human SNAP-23 (hSNAP-23) and has a modified amino acid sequence relative to the wild-type BoNT / AL chain (SEQ ID NO: 1), comprising:

[0306] a) altering an amino acid residue located within the first BoNT / AL chain protease binding pocket of the P182 / D178 binding site for binding hSNAP-23; wherein the first BoNT / AL chain protease binding pocket is defined as amino acid residue E148 of the wild-type BoNT / AL chain (SEQ ID NO: 1); and

[0307] b) altering an amino acid residue located within the fifth BoNT / AL chain protease binding pocket that is located within the R186 binding site for binding hSNAP-23; wherein the fifth BoNT / AL chain protease binding pocket is defined as amino acid residue S143 of the wild-type BoNT / AL chain (SEQ ID NO: 1); and

[0308] c) altering an amino acid residue located within the second BoNT / AL chain protease binding pocket located within the D189 / D192 binding site for binding hSNAP-23; wherein the second BoNT / AL chain protease binding pocket is defined as amino acid residue Q29A of the wild-type BoNT / AL chain (SEQ ID NO: 1); and

[0309] d) an amino acid residue change located within the sixth BoNT / AL chain protease binding pocket for binding to the K206 binding site of hSNAP-23; wherein the sixth BoNT / AL chain protease binding pocket is defined as amino acid residue Y251 of the wild-type BoNT / AL chain (SEQ ID NO: 1); and

[0310] e) wherein the amino acid residue changes comprise:

[0311] i. an amino acid residue selected from tyrosine at the position on the modified L chain protease amino acid sequence corresponding to amino acid residue E148 of the wild-type BoNT / AL chain (SEQ ID NO: 1); and

[0312] ii. an amino acid residue selected from aspartic acid at the position on the modified L chain protease amino acid sequence corresponding to amino acid residue S143 of the wild-type BoNT / AL chain (SEQ ID NO: 1); and

[0313] iii. an amino acid residue selected from alanine at the position on the modified L chain protease amino acid sequence corresponding to amino acid residue Q29 of the wild-type BoNT / AL chain (SEQ ID NO: 1); and

[0314] iv. an amino acid residue selected from glutamic acid at the position on the modified L chain protease amino acid sequence corresponding to amino acid residue Y251 of the wild-type BoNT / AL chain (SEQ ID NO: 1).

[0315] As another or alternative technical feature, the present invention includes a BoNT / AL chain mutant comprising one or more mutations within the BoNT / AL chain binding pocket as defined herein. As an example, a modified BoNT / AL chain of the present invention that cleaves human SNAP-23 (hSNAP-23) has a modified amino acid sequence relative to a wild-type BoNT / AL chain (SEQ ID NO: 1), comprising:

[0316] a) changes in amino acid residues located within the third BoNT / AL chain protease binding pocket for binding to the I198 binding site of hSNAP-23;

[0317] b) wherein the third BoNT / AL chain protease binding pocket is defined as amino acid residue K166 of the wild-type BoNT / AL chain (SEQ ID NO: 1); and

[0318] c) wherein the amino acid residue changes comprise:

[0319] i. An amino acid residue selected from the group consisting of valine, phenylalanine, leucine, and isoleucine at the position on the modified L chain protease amino acid sequence corresponding to amino acid residue K166 of the wild-type BoNT / AL chain (SEQ ID NO: 1).

[0320] Without wishing to be bound by any theory, Applicants believe that the BoNT / AL chain binding pocket defined above may provide a stabilizing hydrophobic interaction between 1198 on hSNAP-23 and amino acid 166 of BoNT / A.

[0321] Modified BoNT / AL chains of the invention comprising binding pocket mutations for the I198 binding site on hSNAP-23 generally exhibit greater than 9% hSNAP-23 cleavage (% of 1 micromolar modified BoNT / AL chain, 20 micromolar hSNAP-23, preferably incubated at about 37°C for about 1 hour) - see Figure 1A For reference, a wild-type BoNT / AL chain (e.g., SEQ ID NO: 1) exhibits less than 0.5% hSNAP-23 cleavage (% of 1 micromolar modified BoNT / AL chain, 20 micromolar hSNAP-23, preferably incubated at about 37°C for about 1 hour) - see Figure 1A Examples of such modified BoNT / AL chains (referred to by amino acid substitution relative to the corresponding wild-type BoNT / AL chain SEQ ID NO: 1) include:

[0322] A modified BoNT / AL chain containing the substitution K166V;

[0323] A modified BoNT / AL chain containing the substitution K166F;

[0324] A modified BoNT / AL chain containing the substitution K166L;

[0325] Modified BoNT / AL chain containing the substitution K166I.

[0326] In one embodiment, a modified BoNT / AL chain of the invention comprising a binding pocket mutation for the I198 binding site on hSNAP-23 generally exhibits greater than 40% hSNAP-23 cleavage (% of 1 micromolar modified BoNT / AL chain, 20 micromolar hSNAP-23, preferably incubated at about 37°C for about 1 hour) - see Figure 1A Examples of such modified BoNT / AL chains (referred to by amino acid substitution relative to the corresponding wild-type BoNT / AL chain SEQ ID NO: 1) include:

[0327] A modified BoNT / AL chain containing the substitution K166F;

[0328] Modified BoNT / AL chain containing the substitution K166L.

[0329] In another embodiment, a modified BoNT / AL chain of the invention comprising a binding pocket mutation for the I198 binding site on hSNAP-23 generally exhibits greater than 60% hSNAP-23 cleavage (% of 1 micromolar modified BoNT / AL chain, 20 micromolar hSNAP-23, preferably incubated at about 37° C. for about 1 hour)—see Figure 1A Examples of such modified BoNT / AL chains (referred to by amino acid substitution relative to the corresponding wild-type BoNT / AL chain SEQ ID NO: 1) include:

[0330] Modified BoNT / AL chain containing the substitution K166F.

[0331] In preferred embodiments, the modified BoNT / AL chains of the invention having binding pocket mutations for the I198 binding site on hSNAP-23 can further comprise one or more mutations within one or more different BoNT / AL chain binding pockets described herein (e.g., within at least two different BoNT / AL chain binding pockets, such as a binding pocket for the P182 / D178 binding site on hSNAP-23 and a binding pocket for the K185 or R186 binding site on hSNAP-23). ​​Such mutants generally exhibit at least 40% hSNAP-23 cleavage (% of 1 micromolar modified BoNT / AL chain, 20 micromolar hSNAP-23, preferably incubated at about 37°C for about 1 hour) - see Figure 1B Examples of such modified BoNT / AL chains (referred to by amino acid substitution relative to the corresponding wild-type BoNT / AL chain SEQ ID NO: 1) include:

[0332] a modified BoNT / AL chain containing substitutions E148Y, K166F, and G305D;

[0333] A modified BoNT / AL chain containing substitutions E148Y, K166V, and G305D;

[0334] Modified BoNT / AL chains containing substitutions E148Y, S143D, and K166F.

[0335] Thus, in another embodiment, a modified BoNT / AL chain protease is provided that cleaves human SNAP-23 (hSNAP-23) and has a modified amino acid sequence relative to the wild-type BoNT / AL chain (SEQ ID NO: 1), comprising:

[0336] a) altering an amino acid residue located within the first BoNT / AL chain protease binding pocket of the P182 / D178 binding site for binding hSNAP-23; wherein the first BoNT / AL chain protease binding pocket is defined as amino acid residue E148 of the wild-type BoNT / AL chain (SEQ ID NO: 1); and

[0337] b) altering an amino acid residue located within the third BoNT / AL chain protease binding pocket that is located within the 1198 binding site for binding to hSNAP-23; wherein the third BoNT / AL chain protease binding pocket is defined as amino acid residue K166 of the wild-type BoNT / AL chain (SEQ ID NO: 1); and

[0338] c) an amino acid residue change located within the fourth BoNT / AL chain protease binding pocket located within the K185 binding site for binding hSNAP-23; wherein the fourth BoNT / AL chain protease binding pocket is defined as amino acid residue G305 of the wild-type BoNT / AL chain (SEQ ID NO: 1);

[0339] d) wherein the amino acid residue changes comprise:

[0340] i. an amino acid residue selected from tyrosine at the position on the modified L chain protease amino acid sequence corresponding to amino acid residue E148 of the wild-type BoNT / AL chain (SEQ ID NO: 1); and

[0341] ii. an amino acid residue selected from valine at the position on the modified L chain protease amino acid sequence corresponding to amino acid residue K166 of the wild-type BoNT / AL chain (SEQ ID NO: 1); and

[0342] iii. an amino acid residue selected from aspartic acid at the position on the modified L chain protease amino acid sequence corresponding to amino acid residue G305 of the wild-type BoNT / AL chain (SEQ ID NO: 1).

[0343] In another embodiment, a modified BoNT / AL chain of the invention having a binding pocket mutation for the I198 binding site on hSNAP-23 can further comprise one or more mutations within at least two different BoNT / AL chain binding pockets (e.g., within a binding pocket for the P182 / D178 binding site on hSNAP-23, and within a binding pocket for the K185 or R186 binding site on hSNAP-23). ​​Such mutants generally exhibit at least 15% hSNAP-23 cleavage (% of 10 nanomoles of modified BoNT / AL chain, 20 micromoles of hSNAP-23, preferably incubated at about 37°C for about 1 hour) - see Figure 1B Examples of such modified BoNT / AL chains (referred to by amino acid substitution relative to the corresponding wild-type BoNT / AL chain SEQ ID NO: 1) include:

[0344] a modified BoNT / AL chain containing substitutions E148Y, K166F, and G305D;

[0345] Modified BoNT / AL chains containing substitutions E148Y, S143D, and K166F.

[0346] In one embodiment, a modified BoNT / AL chain of the invention having a binding pocket mutation for the I198 binding site on hSNAP-23 can further comprise one or more mutations within at least three different BoNT / AL chain binding pockets (e.g., within a binding pocket for the P182 / D178 binding site on hSNAP-23, within a binding pocket for the D189 / D192 binding site on hSNAP-23, and within a binding pocket for the K185 binding site on hSNAP-23, as defined above). Such mutants generally exhibit at least 60% hSNAP-23 cleavage (% of 1 micromolar modified BoNT / AL chain, 20 micromolar hSNAP-23, preferably incubated at about 37°C for about 1 hour) - see Figure 1B Examples of such modified BoNT / AL chains (referred to by amino acid substitution relative to the corresponding wild-type BoNT / AL chain SEQ ID NO: 1) include:

[0347] a modified BoNT / AL chain containing substitutions E148Y, Q29A, K166V, and G305D;

[0348] Modified BoNT / AL chains containing substitutions E148Y, Q29A, K166F, and G305D.

[0349] Thus, in another embodiment, a modified BoNT / AL chain protease is provided that cleaves human SNAP-23 (hSNAP-23) and has a modified amino acid sequence relative to the wild-type BoNT / AL chain (SEQ ID NO: 1), comprising:

[0350] a) altering an amino acid residue located within the first BoNT / AL chain protease binding pocket of the P182 / D178 binding site for binding hSNAP-23; wherein the first BoNT / AL chain protease binding pocket is defined as amino acid residue E148 of the wild-type BoNT / AL chain (SEQ ID NO: 1); and

[0351] b) altering an amino acid residue located within the third BoNT / AL chain protease binding pocket that is located within the 1198 binding site for binding to hSNAP-23; wherein the third BoNT / AL chain protease binding pocket is defined as amino acid residue K166 of the wild-type BoNT / AL chain (SEQ ID NO: 1); and

[0352] c) altering an amino acid residue located within the second BoNT / AL chain protease binding pocket located within the D189 / D192 binding site for binding hSNAP-23; wherein the second BoNT / AL chain protease binding pocket is defined as amino acid residue Q29A of the wild-type BoNT / AL chain (SEQ ID NO: 1); and

[0353] d) an amino acid residue change located within the fourth BoNT / AL chain protease binding pocket located within the K185 binding site for binding hSNAP-23; wherein the fourth BoNT / AL chain protease binding pocket is defined as amino acid residue G305 of the wild-type BoNT / AL chain (SEQ ID NO: 1);

[0354] e) wherein the amino acid residue changes comprise:

[0355] i. an amino acid residue selected from tyrosine at the position on the modified L chain protease amino acid sequence corresponding to amino acid residue E148 of the wild-type BoNT / AL chain (SEQ ID NO: 1); and

[0356] ii. an amino acid residue selected from valine at the position on the modified L chain protease amino acid sequence corresponding to amino acid residue K166 of the wild-type BoNT / AL chain (SEQ ID NO: 1); and

[0357] iii. an amino acid residue selected from alanine at the position on the modified L chain protease amino acid sequence corresponding to amino acid residue Q29 of the wild-type BoNT / AL chain (SEQ ID NO: 1); and

[0358] iv. an amino acid residue selected from aspartic acid at the position on the modified L chain protease amino acid sequence corresponding to amino acid residue G305 of the wild-type BoNT / AL chain (SEQ ID NO: 1).

[0359] In another embodiment, a modified BoNT / AL chain of the invention having a binding pocket mutation for the I198 binding site on hSNAP-23 can further comprise one or more mutations within at least three different BoNT / AL chain binding pockets (e.g., within a binding pocket for the P182 / D178 binding site on hSNAP-23, within a binding pocket for the D189 / D192 binding site on hSNAP-23, and within a binding pocket for the K185 binding site on hSNAP-23). ​​Such mutants generally exhibit at least 10% hSNAP-23 cleavage (% of 10 nanomoles of modified BoNT / AL chain, 20 micromoles of hSNAP-23, preferably incubated at about 37°C for about 1 hour) - see Figure 1BExamples of such modified BoNT / AL chains (referred to by amino acid substitution relative to the corresponding wild-type BoNT / AL chain SEQ ID NO: 1) include:

[0360] Modified BoNT / AL chains containing substitutions E148Y, Q29A, K166F, and G305D.

[0361] Other examples of modified BoNT / AL chain mutants having binding pocket mutations for I198 on hSNAP-23 (referred to by amino acid substitution relative to the corresponding wild-type BoNT / AL chain SEQ ID NO: 1) include:

[0362] Modified BoNT / AL chains containing substitutions E148Y, Q29A, K166F, Y251E, and G305D.

[0363] In one embodiment, a modified BoNT / AL chain of the invention having a binding pocket mutation for the I198 binding site on hSNAP-23 can further comprise one or more mutations within one or more different BoNT / AL chain binding pockets (e.g., within a binding pocket for the P182 / D178 binding site on hSNAP-23, or within a binding pocket for the K185 binding site on hSNAP-23, as defined above). Such mutants generally exhibit at least 3% hSNAP-23 cleavage (% of 10 nanomoles of modified BoNT / AL chain, 20 micromoles of hSNAP-23, preferably incubated at about 37°C for about 1 hour) - see Figure 1B Examples of such modified BoNT / AL chains (referred to by amino acid substitution relative to the corresponding wild-type BoNT / AL chain SEQ ID NO: 1) include:

[0364] A modified BoNT / AL chain containing substitutions E148Y and K166F;

[0365] Modified BoNT / AL chain containing substitutions G305D and K166F.

[0366] In another embodiment, a modified BoNT / AL chain of the invention having a binding pocket mutation for the I198 binding site on hSNAP-23 can further comprise one or more mutations within one or more different BoNT / AL chain binding pockets (e.g., within a binding pocket for the P182 / D178 binding site on hSNAP-23, or within a binding pocket for the K185 binding site on hSNAP-23). ​​Such mutants generally exhibit at least 5% hSNAP-23 cleavage (% of 10 nanomoles of modified BoNT / AL chain, 20 micromoles of hSNAP-23, preferably incubated at about 37°C for about 1 hour) - see Figure 1B Examples of such modified BoNT / AL chains (referred to by amino acid substitution relative to the corresponding wild-type BoNT / AL chain SEQ ID NO: 1) include:

[0367] Modified BoNT / AL chains containing substitutions E148Y and K166F.

[0368] As another or alternative technical feature, the present invention includes a BoNT / AL chain mutant comprising one or more mutations within the BoNT / AL chain binding pocket as defined herein. As an example, a modified BoNT / AL chain of the present invention that cleaves human SNAP-23 (hSNAP-23) has a modified amino acid sequence relative to a wild-type BoNT / AL chain (SEQ ID NO: 1), comprising:

[0369] a) changes in amino acid residues located within the seventh BoNT / AL chain protease binding pocket of the D210 binding site for binding to hSNAP-23;

[0370] b) wherein the seventh BoNT / AL chain protease binding pocket is defined as amino acid residue S254 of the wild-type BoNT / AL chain (SEQ ID NO: 1);

[0371] c) wherein the amino acid residue changes comprise:

[0372] i. For example, an amino acid residue alanine at the position of the modified L chain protease amino acid sequence corresponding to amino acid residue S254 of the wild-type BoNT / AL chain (SEQ ID NO: 1).

[0373] Without wishing to be bound by any theory, Applicants believe that the BoNT / AL chain binding pocket defined above can exhibit hydrogen bonding with the D210 binding site of hSNAP-23. Furthermore, Applicants believe that modification of the binding pocket (as defined herein) eliminates the hydrogen bond that would otherwise form between D210 on hSNAP-23 and amino acid 254 of BoNT / A. This in turn is believed to produce a C-terminal hSNAP-23 cleavage product in the form of a better "leaving group," thereby enhancing the hSNAP-23 cleavage rate.

[0374] Examples of such modified BoNT / AL chains (referred to by amino acid substitution relative to the corresponding wild-type BoNT / AL chain SEQ ID NO: 1) include:

[0375] Modified BoNT / AL chain containing the substitution S254A.

[0376] In one embodiment, a modified BoNT / AL chain of the invention having a binding pocket mutation for the D210 binding site on hSNAP-23 can further comprise one or more mutations within one or more different BoNT / AL chain binding pockets described herein (e.g., within at least two or three different BoNT / AL chain binding pockets, such as a binding pocket for the P182 / D178 binding site on hSNAP-23, a binding pocket for the I198 binding site on hSNAP-23, and optionally a binding pocket for the K185 binding site on hSNAP-23). ​​Such mutants generally exhibit at least 10% hSNAP-23 cleavage (% of 10 nanomoles of modified BoNT / AL chain, 20 micromoles of hSNAP-23, preferably incubated at about 37°C for about 1 hour) - see Figure 1B Examples of such modified BoNT / AL chains include:

[0377] a modified BoNT / AL chain containing substitutions E148Y, K166F, and S254A;

[0378] Modified BoNT / AL chains containing substitutions E148Y, K166F, S254A, and G305D.

[0379] In preferred embodiments, the modified BoNT / AL chains of the invention having binding pocket mutations for the D210 binding site on hSNAP-23 can further comprise one or more mutations within one or more different BoNT / AL chain binding pockets described herein (e.g., within at least three different BoNT / AL chain binding pockets, such as a binding pocket for the P182 / D178 binding site on hSNAP-23, a binding pocket for the I198 binding site on hSNAP-23, and a binding pocket for the K185 binding site on hSNAP-23). ​​Such mutants generally exhibit at least 25% hSNAP-23 cleavage (% of 10 nanomoles of modified BoNT / AL chain, 20 micromoles of hSNAP-23, preferably incubated at about 37°C for about 1 hour) - see Figure 1B Examples of such modified BoNT / AL chains (referred to by amino acid substitution relative to the corresponding wild-type BoNT / AL chain SEQ ID NO: 1) include:

[0380] Modified BoNT / AL chains containing substitutions E148Y, K166F, S254A, and G305D.

[0381] As another or alternative technical feature, the present invention includes a BoNT / AL chain mutant comprising one or more mutations within the BoNT / AL chain binding pocket as defined herein. As an example, a modified BoNT / AL chain of the present invention that cleaves human SNAP-23 (hSNAP-23) has a modified amino acid sequence relative to a wild-type BoNT / AL chain (SEQ ID NO: 1), comprising:

[0382] a) changes in amino acid residues located within the eighth BoNT / AL chain protease binding pocket of the D168 binding site for binding to hSNAP-23;

[0383] b) wherein the eighth BoNT / AL chain protease binding pocket is defined as amino acid residue K340 of the wild-type BoNT / AL chain (SEQ ID NO: 1);

[0384] c) wherein the amino acid residue changes comprise:

[0385] i. For example, the amino acid residue histidine at the position of the modified L chain protease amino acid sequence corresponding to amino acid residue K340 of the wild-type BoNT / AL chain (SEQ ID NO: 1).

[0386] Without wishing to be bound by any theory, Applicants believe that the BoNT / AL chain binding pocket defined above provides a salt bridge between D168 on hSNAP-23 and amino acid 340 of BoNT / A.

[0387] Examples of such modified BoNT / AL chains (referred to by amino acid substitution relative to the corresponding wild-type BoNT / AL chain SEQ ID NO: 1) include:

[0388] Modified BoNT / AL chains containing the substitution K340H.

[0389] In one embodiment, a modified BoNT / AL chain of the invention having a binding pocket mutation for the P182 / D178 binding site on hSNAP-23 can further comprise one or more mutations within the BoNT / AL chain binding pocket for the D168 binding site on hSNAP-23. Such mutants generally exhibit at least 3% hSNAP-23 cleavage (% of 1 micromolar modified BoNT / AL chain, 20 micromolar hSNAP-23, preferably incubated at about 37°C for about 1 hour) - see Figure 1B Examples of such modified BoNT / AL chains (referred to by amino acid substitution relative to the corresponding wild-type BoNT / AL chain SEQ ID NO: 1) include:

[0390] Modified BoNT / AL chains containing substitutions E148Y and K340H.

[0391] The modified BoNT / AL chain protease described above may comprise an amino acid sequence having at least 70%, such as at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, or at least 99% sequence identity to the wild-type BoNT / AL chain (SEQ ID NO: 1). As previously mentioned, the modified BoNT / AL chain protease referred to throughout this specification encompasses its functional fragments, i.e., fragments of the protease that cleave hSNAP-23. For example, the modified BoNT / AL chain protease of the present invention comprises at least 300 (e.g., at least 350, at least 400, or at least 410) amino acids. As an example, the N-terminal 8 amino acids and / or the carboxyl terminus (e.g., the last 32 amino acids) of the botulinum neurotoxin L chain protease are not required for proteolytic activity.

[0392] The modified BoNT / AL chains of the present invention can be PEGylated to improve stability, e.g., duration of action of protease components. PEGylation preferably comprises adding PEG to the N-terminus of the L chain. As an example, the N-terminus of the L chain can be extended with one or more amino acid (e.g., cysteine) residues. One or more of the amino acid residues can have their own PEG molecule attached (e.g., covalently attached) thereto. Examples of this technology are described in WO2007 / 104567, which is incorporated herein by reference in its entirety.

[0393] The modified BoNT / AL chains of the present invention may include the addition (or removal) of a "second modification site" - see WO2002 / 040506, US7223577, and WO2005 / 068494, each of which is hereby incorporated by reference in its entirety. The additional presence or absence of such a site (relative to a wild-type BoNT L chain) alters the biological persistence (e.g., biological half-life) of the modified L chains of the present invention.

[0394] A second aspect of the invention provides a nucleic acid construct comprising or containing a nucleic acid sequence encoding a modified BoNT / AL chain as described herein. The nucleic acid sequence may preferably encode a TSI delivery vector as further described below. The nucleic acid construct of the invention may comprise conventional regulatory elements, such as a promoter and / or terminator.

[0395] In one embodiment, the nucleic acid construct is provided in the form of a bacterial plasmid or a viral vector. The nucleic acid construct can optionally be subjected to codon bias processing to optimize expression (eg, recombinant expression) in a target host cell (eg, E. coli).

[0396] In one embodiment, a nucleic acid construct encoding a modified BoNT / AL chain as described herein can be administered to a target cell of interest, such as for therapeutic or cosmetic purposes. To this end, the nucleic acid construct is typically optimized in a conventional manner for delivery into a target cell, preferably a human cell (and then expressed in the target cell). The target cell is preferably a non-neuronal cell.

[0397] A third aspect of the present invention provides a delivery vector for a modified BoNT / AL chain, thereby facilitating the entry of the modified BoNT / AL chain into a target cell of interest. According to this aspect, the present invention more particularly relates to a delivery vector comprising:

[0398] a) a modified BoNT / AL chain protease of the invention or a nucleic acid construct comprising or consisting of a nucleic acid sequence encoding a modified BoNT / AL chain of the invention; and

[0399] b) elements for delivering the modified BoNT / AL chain protease or the nucleic acid construct to target cells.

[0400] Preferred elements for such delivery include any conventional delivery vehicle technology known in the art, such as liposomes, biolistic particles, cell penetrating peptides, gene transfer vectors, and the like.

[0401] A particularly preferred delivery technology that is highly suitable for use in the present invention is the applicant's proprietary targeted secretion inhibitor (TSI) technology. The basic methods for producing TSIs are well documented and are now considered conventional methods (see, for example, WO98 / 07864, WO2006 / 059113, WO2009 / 150469, WO2010 / 020811, WO2009 / 150470, WO2010 / 094905, WO2012 / 156743, each of which is incorporated herein by reference in its entirety). TSI technology relies on a delivery mechanism that mimics the same basic steps (i.e., binding to target cells, endosome formation, L chain translocation into the cytosol, cleavage of SNARE proteins by L chain proteolysis) that clostridial neurotoxins utilize when intoxicating host cells. The TSI delivery vector is based on a simple clostridial neurotoxin backbone with three basic components:

[0402] 1) Clostridial neurotoxin L chain;

[0403] 2) A targeting moiety (TM) that directs the delivery vector to the selected target cell. Typically, the natural clostridial neurotoxin binding domain (Hcc) can be replaced with a ligand to provide the delivery vector with selective binding to target cells of interest other than the natural target cells of the Hcc. In a preferred embodiment, more than one TM (optionally including a clostridial neurotoxin binding domain) can be used;

[0404] 3) A translocation peptide (e.g., Clostridial neurotoxin H) that ensures delivery of the Clostridial neurotoxin L chain into target cells where it can then exert its proteolytic action (i.e., cleave SNARE proteins) N translocation domain).

[0405] Therefore, in a preferred embodiment, element b) of the delivery vehicle of the present invention may comprise:

[0406] -i) a targeting moiety (TM) that allows the delivery vector to bind to the target cell. The targeting moiety may be a natural Clostridial neurotoxin binding domain (H CC ), or more preferably, providing CC a ligand that binds to a target cell other than the natural target cell of the molecule; and

[0407] -ii) a translocation peptide that translocates the modified BoNT / AL chain protease of the present invention into a target cell, preferably into the cytosol of the cell.

[0408] The delivery vectors of the present invention typically include one or more targeting moieties (TMs). Reference to a TM encompasses any structure (typically a peptide) that functionally interacts with a site (e.g., a receptor or acceptor) resulting in physical association between the modified BoNT / AL chain protease of the present invention and the surface of a mammalian target cell (e.g., a human cell). The site is preferably one that is capable of internalization (e.g., endosome formation), also known as receptor-mediated endocytosis. The TM may have endosomal membrane translocation function, in which case there is no need to utilize separate TM and translocation domain components.

[0409] The TM of the present invention binds (e.g., specifically binds) to the selected target cell. The term "specifically binds" preferably refers to a given TM binding to (e.g., specifically binding to) a selected target cell. 6 M -1 or higher, such as 10 7 M -1 or higher, 10 8 M -1 or higher, or 10 9 M -1 or higher binding affinity (Ka) to bind to target cells.

[0410] It is routine to confirm that the TM binds to the selected target cells. For example, a simple radioactive substitution experiment can be used, in which tissues or cells representing the target cells of interest are exposed to labeled (e.g., tritiated) TM in the presence of an excess of unlabeled TM. In such an experiment, the relative proportions of nonspecific and specific binding can be assessed, thereby allowing confirmation that the TM binds to the target cells. Optionally, the assay can include one or more binding antagonists, which can further include observing the loss of TM binding. Examples of such experiments can be found in Hulme, EC (1990), Receptor-binding studies, a brief outline, 303-311 pages, In Receptor biochemistry, A Practical Approach, Ed. ECHulme, Oxford University Press.

[0411] The TMs of the invention preferably bind to non-neuronal target cells (e.g., mast cells and / or epithelial cells—see, e.g., WO00 / 10598 and WO01 / 21213, each of which is hereby incorporated by reference in its entirety). To this end, the TM is capable of directing the delivery vector to selected non-neuronal target cells that exhibit an undesirable hSNAP-23 phenotype (optionally an undesirable SNAP-25 phenotype). At the same time, the TMs of the invention can separately (e.g., via the same TM or via a second TM) bind to a selected second target cell, e.g., bind to a second non-neuronal target cell or bind to a neuronal target cell that exhibits an undesirable hSNAP-23 and / or SNAP-25 phenotype.

[0412] Suitable TMs include: ligands for mammalian cell binding site receptors such as cytokines, growth factors, neuropeptides, lectins and antibodies - this term includes monoclonal antibodies, single chain antibodies and antibody fragments such as Fab, F(ab)' 2 , Fv, ScFv, etc.

[0413] By further example, TMs include leptin peptides, growth hormone releasing peptide receptor, somatostatin peptides, insulin growth factor peptides, ErbB peptides (e.g., EGF), VIP glucagon GRF secretion peptides (e.g., PACAP peptides), interleukin peptides (e.g., IL-1, IL-2, IL-6, or IL-10 peptides), NGF peptides, VEGF peptides, bombesin peptides, urotensin, melanin concentrating hormone peptides, prolactin releasing hormone peptides, KiSS-1 peptides, CRF peptides, GHRH peptides, substance P peptides, beta-2 adrenergic receptor peptides, gastrin releasing peptide, calcitonin gene-related peptide, platelet-derived growth factor peptides, keratinocyte growth factor peptides, hepatocyte growth factor peptides, TGF-alpha peptides, TGF-beta peptides, atrial natriuretic peptides, and integrin peptides.

[0414] The delivery vectors of the invention typically lack a (functional) Clostridial neurotoxin binding domain (as a TM).

[0415] Alternatively, the delivery vector of the invention may include a (functional) clostridial neurotoxin binding domain (as a TM). Reference to a clostridial neurotoxin binding domain encompasses a clostridial neurotoxin binding domain. C (More precisely, H CC ) part, and its retention H C Mutants that modify the binding capacity of the 3,4-dihydropyrimidine domain (eg, binding to rat synaptosomal membranes in a conventional binding assay such as that described in Shone et al. (1985) Eur. J. Biochem. 151, 75-82).

[0416] H of natural clostridial neurotoxin CThe binding domain / peptide contains approximately 400-440 amino acid residues and consists of two functionally distinct domains of approximately 25 kDa each, the N-terminal region (usually referred to as the H CN peptide or domain) and the C-terminal region (often referred to as H CC It is the C-terminal region (H CC ) is responsible for the binding of clostridial neurotoxins (to nerve endings at the neuromuscular junction). Exemplary H CC Peptides include:

[0417] Botulinum neurotoxin type A - amino acid residues (Y1111-L1296)

[0418] Botulinum neurotoxin type B - amino acid residues (Y1098-E1291)

[0419] Botulinum neurotoxin type C - amino acid residues (Y1112-E1291)

[0420] Botulinum neurotoxin type D - amino acid residues (Y1099-E1276)

[0421] Botulinum neurotoxin type E - amino acid residues (Y1086-K1252)

[0422] Botulinum neurotoxin type F - amino acid residues (Y1106-E1274)

[0423] Botulinum neurotoxin type G - amino acid residues (Y1106-E1297)

[0424] Tetanus neurotoxin - amino acid residues (Y1128-D1315).

[0425] The reference sequences identified above should be considered as a guide, as slight variations may exist depending on the subserotype.

[0426] The delivery vector of the present invention generally includes a translocation peptide that enables the modified L chain to translocate into the cytosol of the target. Any of a number of conventional assays can be used to confirm whether the peptide has the translocation function necessary for the present invention. For example, Shone C. (1987) describes an in vitro assay using liposomes, in which the liposomes are challenged with a test molecule. The K +The presence of the necessary translocation function is confirmed by the release of and / or labeled NAD from the liposomes [see Shone C. (1987) Eur. J. Biochem; 167 (1): 175-180]. Blaustein R. (1987) provides another example, which describes a simple in vitro assay using a planar phospholipid bilayer membrane. The membrane is attacked with a test molecule and the necessary translocation function is confirmed by an increase in the conductance across the membrane [see Blaustein (1987) FEBS Letts; 226, 1: 115-120]. Methods in Enzymology 220 and 221, Membrane Fusion Techniques, Parts A and B, Academic Press 1993 provide other methods that enable the assessment of membrane fusion and thus the identification of translocation domains suitable for use in the present invention.

[0427] The translocation domain may be of Clostridial origin, such as the H N Domain / part. N The term "domain" refers to a fragment of the H chain of a clostridial neurotoxin that is approximately equal to the amino-terminal half of the H chain. N Domain lacks H chain H C The natural binding function of the ingredients. N The domain is unable to bind to the binding site on the target cell to which the native Clostridial neurotoxin (ie, the holotoxin) binds.

[0428] Examples of suitable (reference) translocation domains include:

[0429] Botulinum neurotoxin type A - amino acid residues (449-871)

[0430] Botulinum neurotoxin type B - amino acid residues (441-858)

[0431] Botulinum neurotoxin type C - amino acid residues (442-866)

[0432] Botulinum neurotoxin type D - amino acid residues (446-862)

[0433] Botulinum neurotoxin type E - amino acid residues (423-845)

[0434] Botulinum neurotoxin type F - amino acid residues (440-864)

[0435] Botulinum neurotoxin type G - amino acid residues (442-863)

[0436] Tetanus neurotoxin - amino acid residues (458-879)

[0437] Studies have shown that the full-length H from the heavy chain of Clostridial neurotoxin N The portion is not essential for translocation activity. Thus, aspects of this embodiment may include Clostridial toxin H N Regions comprising translocation domains having, for example, a length of at least 350 amino acids, at least 375 amino acids, at least 400 amino acids, and at least 425 amino acids. For further details on the genetic basis of toxin production in C. botulinum and C. tetani, we refer to Henderson et al. (1997), The Clostridia: Molecular Biology and Pathogenesis, Academic press.

[0438] Terminology N Covers naturally occurring neurotoxin H N Parts, and variants H having amino acid sequences not found in nature N part, as long as the variant H N Some of them still show the above translocation function. For example, Clostridial neurotoxin H N Partially covered with wild-type Clostridial neurotoxin H N Variant amino acid sequences having at least 70% (e.g., at least 80% or at least 85% or at least 90% or at least 95% or at least 97% or at least 98% or at least 99%) sequence identity are described in detail below, provided that the translocation function is retained.

[0439] Alternatively, the translocation peptide may be of non-Clostridial origin, such as the translocation domain of diphtheria toxin [O. Keefe et al., Proc. Natl. Acad. Sci. USA (1992) 89, 6202-6206; Silverman et al., J. Biol. Chem. (1993) 269, 22524-22532; and London, E. (1992) Biochem. Biophys. Acta., 1112, pp. 25-51], the translocation domain of Pseudomonas exotoxin type A [Prior et al. Biochemistry (1992) 31, 3555-3559], the translocation domain of anthrax toxin [Blanke et al., Proc. Natl. Acad. Sci. USA (1992) 89, 6202-6206; Silverman et al., J. Biol. Chem. (1993) 269, 22524-22532; and London, E. (1992) Biochem. Biophys. Acta., 1112, pp. 25-51], the translocation domain of Pseudomonas exotoxin type A [Prior et al. Biochemistry (1992) 31, 3555-3559], the translocation domain of anthrax toxin [Blanke et al., Proc. Natl. Acad. Sci. USA (1996) 93, 8437-8442], various fusion or hydrophobic peptides with translocation function [Plank et al., J. Biol. Chem. (1994) 269, 12918-12924; and Wagner et al. (1992) PNAS, 89, pp. 7934-7938] and amphiphilic peptides [Murata et al. (1992) Biochem., 31, pp. 1986-1992].

[0440] Reference to a non-Clostridial neurotoxin translocation peptide encompasses fragments and variant amino acid sequences having at least 70% (e.g., at least 80% or at least 85% or at least 90% or at least 95% or at least 97% or at least 98% or at least 99%) sequence identity to the corresponding non-Clostridial wild-type translocation peptide sequence, provided that the variant has the requisite translocation function.

[0441]

[0442] The polypeptides of the invention may further comprise a translocation facilitating domain. Such domains facilitate the delivery of non-cytotoxic proteases into the cytosol of target cells and are described, for example, in WO 08 / 008803 and WO 08 / 008805, each of which is incorporated herein by reference.

[0443] As an example, suitable translocation facilitating domains include enveloped virus fusion peptide domains, for example, suitable fusion peptide domains include influenza virus fusion peptide domains (e.g., 23 amino acids of influenza A virus fusion peptide domain), alphavirus fusion peptide domains (e.g., 26 amino acids of Semliki Forest virus fusion peptide domain), vesicular virus fusion peptide domains (e.g., 21 amino acids of vesicular stomatitis virus fusion peptide domain), respiratory virus fusion peptide domains (e.g., 25 amino acids of Sendai virus fusion peptide domain), measles virus (morbiliivirus) fusion peptide domain (e.g., 25 amino acids of canine distemper virus fusion peptide domain), avulavirus fusion peptide domain (e.g., 25 amino acids of Newcastle disease virus fusion peptide domain), hennivirus fusion peptide domain (e.g., 25 amino acids of Hendra virus fusion peptide domain), metapneumovirus fusion peptide domain (e.g., 25 amino acids of human metapneumovirus fusion peptide domain), or foamy virus fusion peptide domains such as simian foamy virus fusion peptide domain; or fragments or variants thereof.

[0444] As a further example, the translocation facilitating domain may comprise a Clostridial neurotoxin H CN domain or fragment or variant (having at least 70% sequence identity to the corresponding wild-type sequence), provided that the enhanced translocation function is retained. CN The translocation facilitating domain can have a length of at least 200 amino acids, at least 225 amino acids, at least 250 amino acids, at least 275 amino acids. In this regard, the Clostridial toxin H CN The translocation facilitating domain preferably has a length of at most 200 amino acids, at most 225 amino acids, at most 250 amino acids, or at most 275 amino acids. Specific (reference) examples include:

[0445] Botulinum neurotoxin type A - amino acid residues (872-1110)

[0446] Botulinum neurotoxin type B - amino acid residues (859-1097)

[0447] Botulinum neurotoxin type C - amino acid residues (867-1111)

[0448] Botulinum neurotoxin type D - amino acid residues (863-1098)

[0449] Botulinum neurotoxin type E - amino acid residues (846-1085)

[0450] Botulinum neurotoxin type F - amino acid residues (865-1105)

[0451] Botulinum neurotoxin type G - amino acid residues (864-1105)

[0452] Tetanus neurotoxin - amino acid residues (880-1127).

[0453] A fourth aspect of the invention provides a method of cleaving hSNAP-23, the method comprising contacting hSNAP-23 with a modified BoNT / AL chain protease, or a nucleic acid construct, or a delivery vector as described herein, thereby allowing the modified BoNT / AL chain to bind to the hSNAP-23, followed by proteolytic cleavage of the hSNAP-23 by the modified BoNT / AL chain protease. In one embodiment, the method is performed in vitro.

[0454] In one embodiment, the method of cleaving hSNAP-23 comprises the following preliminary steps:

[0455] 1) The delivery vector binds to the target cell via its targeting moiety (TM); and

[0456] 2) The modified BoNT / AL chain is translocated into the target cell, preferably into the cytosol of the target cell, via the translocation peptide of the delivery vector.

[0457] Preferably, the TM binds to a site on the target cell (e.g., a protein, sugar, and / or lipid molecule) that is capable of receptor-mediated endocytosis, and the delivery vehicle is then internalized within the target cell via endosome formation. The translocation peptide of the delivery vehicle can then translocate the modified BoNT / AL chain across the endosomal membrane and into the cytosol of the target cell.

[0458] In another aspect, the present invention relates to a modified (BoNT / A) L chain protease, nucleic acid construct, or delivery vector described herein, for use in the method of cleaving hSNAP23 described above.

[0459] In another aspect, the present invention encompasses the modified (BoNT / A) L chain proteases described herein for use in a method of treatment, preferably a method of treating a secretory disease.

[0460] Thus, in one aspect, a BoNT / AL chain protease as described herein, or a nucleic acid construct as described herein, or a delivery vector as described herein is provided for use as a medicament.

[0461] In such aspects, the modified (BoNT / A) L chain protease is preferably contained within a BoNT that also contains a heavy chain, i.e., a full-length BoNT. Such full-length BoNTs typically have a 150 kDa polypeptide chain, comprising a 100 kDa heavy chain and a 50 kDa light chain linked by disulfide bonds, organized into three functional domains: an N-terminal proteolytic light chain (L chain) and a C-terminal heavy chain (H chain), the latter consisting of a translocation domain (H chain). N ) and the C-terminal neuron binding domain (H C )composition.

[0462] Preferred secretory disorders include muscle spasms / muscle overactivity (including post-stroke spasticity, post-spinal cord injury spasticity, head and neck spasms, blepharospasm, vaginismus, limb spasms, jaw spasms and vocal cord spasms), strabismus, hyperhidrosis and severe primary axillary hyperhidrosis.

[0463] According to the embodiments described in detail below, the present invention will be better understood. However, it will be appreciated by those skilled in the art that this detailed description is not limiting and that various modifications, substitutions, omissions and changes may be made without departing from the scope of the present invention.

[0464] Description of the drawings

[0465] Figure 1 - hSNAP-23 and hSNAP25 cleavage data for modified BoNT / AL chain proteases of the invention. (A) Data for BoNT / AL chain proteases with mutations in a single binding pocket, (B) Data for BoNT / AL chain proteases with mutations in multiple binding pockets.

[0466] Figure 2 - 3D rendered image of the interaction of BoNT / AL chain protease (outline) with the SNAP-25 / 23 binding pocket (line rendering).

[0467] Amino acid sequence

[0468] SEQ ID NO: 1—Wild-type BoNT / A light chain (amino acid residues 1-438 of Uniprot A5HZZ9)

[0469] MPFVNKQFNYKDPVNGVDIAYIKIPNAGQMQPVKAFKIHNKIWVIPERDTFTNPEEGDLNPPPEAKQVPVSYYDSTYLSTDNEKDNYLKGVTKLFERIYSTDLGRMLLTSIVRGIPFWGGSTIDTELKVIDTNCINVIQPDGSYRSEELNLVIIGPSADIIQFECKSFGHEVLNLTRNGYGSTQYIRFSPDFTFGFEESLEVDTNPLLGAGKFATDPAVTLAHELIHAGHRLYGIAINPNRVFKVNTNAYYEMSGLEVSFEELRTFGGHDAKFIDSLQENEFRLYYYNKFKDIASTLNKAKSIVGTTASLQYMKNVFKEKYLLSEDTSGKFSVDKLKFDKLYKMLTEIYTEDNFVKFFKVLNRKTYLNFDKAVFKINIVPKVNYTIYDGFNLRNTNLAANFNGQNTEINNMNFTKLKNFTGLFEFYKLLCVRGIITSK

[0470] SEQ ID NO:2 - Human SNAP23

[0471] MDNLSSEEIQQRAHQITDESLESTRRILGLAIESQDAGIKTITMLDEQKEQLNRIEEGLDQINKDMRETEKTLTELNKCCGLCVCPCNRTKNFESGKAYKTTWGDGGENSPCNVVSKQPGPVTNGQLQQPTTGAASGGYIKRITNDAREDEMEENLTQVGSILGNLKDMALNIGNEIDAQNPQIKRITDKADTNRDRIDIANARAKKLIDS

[0472] SEQ ID NO:3 - Human and Rodent SNAP25

[0473] MAEDADMRNELEEMQRRADQLADESLESTRRMLQLVEESKDAGIRTLVMLDEQGEQLERIEEGMDQINKDMKEAEKNLTDLGKFCGLCVCPCNKLKSSDAYKKAWGNNQDGVVASQPARVVDEREQMAISGGFIRRVTNDARENEMDENLEQVSGIIGNLRHMALDMGNEIDTQNRQIDRIMEKADSNKTRIDEANQRATKMLGSG

[0474] SEQ ID NO:4—IgA-protease site His6 tag (artificial)

[0475] PPTPGHHHHHH

[0476] SEQ ID NO:5—Double Strep Tag (Artificial)

[0477] MASWSHPQFEKGGGSGGGSGGGSWSHPQFEKGAGS

[0478] SEQ ID NO:6—His6 tag (artificial)

[0479] GHHHHHH

[0480] SEQ ID NO:7-V-IgA-Protease site His6 tag (artificial)

[0481] VPPTPGHHHHHH

[0482] SEQ ID NO:8—Wild-type BoNT / A1

[0483]

[0484] SEQ ID NO:9-LH N Connector (artificial)

[0485] VRGIITSKTKSLDKGYNKALNDL

[0486] SEQ ID NO:10—Enterokinase activation site

[0487] DDDDK

[0488] SEQ ID NO:11 - BoNT / A1 activation loop

[0489] VDGIITSKTKSDDDDKNKALNLQ Example

[0490] Example 1 - Preparation of Modified BoNT / AL Chains (BoNT / A LC) of the Invention

[0491] Plasmid pBN3 encoding the wild-type BoNT / AL chain (amino acids 1-448, SEQ ID NO: 1) was generated by PCR and appropriate oligonucleotide primers using bacterial DNA from strain 62A as a template. DNA encoding the amino acid sequence PPTPGHHHHHH (SEQ ID NO: 4) was inserted after the codon for amino acids Ala-449. E. coli strain M15pREP4 (Qiagen, Hilden, Germany) was transfected with pBN3 containing the wt BoNT / A LC or its mutants (i.e., the protease mutants of SEQ ID NO: 1 described in this application). For each transfected E. coli strain, 500 ml of 2YT medium was inoculated with a single bacterial colony grown overnight in 5 ml of 2YT medium.

[0492] After the culture OD600 reached 0.7, BoNT / AL chains were produced during 15 hours of induction with 0.2 mM IPTG at 21°C. Bacteria were collected by centrifugation and frozen overnight at -20°C. The bacteria were resuspended in lysis buffer (300 mM NaCl, 50 mM phosphate, pH 8.0) supplemented with benzamidine, pepstatin A and PMSF at final concentrations of 5 mM, 1 μg / ml and 0.5 mM, respectively, lysed by sonication, and the lysate was clarified by centrifugation at 29000 g for 30 minutes to bind the BoNT / AL chains to Ni2+-nitrilotriacetic acid agarose beads. The beads were washed with 20 column volumes of lysis buffer containing 10 mM imidazole, and the BoNT / AL chains were eluted by lysis buffer containing 100 mM imidazole. The fractions containing the target protein were dialyzed against toxin assay buffer (150 mM potassium glutamate, 10 mM Hepes-KOH, pH 7.2), and the purified L chain was finally frozen in liquid nitrogen and stored at -70°C.

[0493] Example 2 - hSNAP-23 cell-free cleavage assay

[0494] The hSNAP-23 (SEQ ID NO: 2) plasmid pS3-hSNAP-23His6 was generated for E. coli expression and in vitro transcription / translation. It encodes a double strep tag fused to the N-terminus (MASWSHPQFEKGGGSGGGSGGGSWSHPQFEKGAGS, SEQ ID NO: 5) and a His6 tag fused to the C-terminus downstream of the codon for Serine 211 at the carboxy terminus (GHHHHHH, SEQ ID NO: 6).

[0495] For protein production and purification, pS3-hSNAP-23His6 was transfected into E. coli strain BL21-DE3 (Stratagene Europe, Ebsdorfergrund, Germany) and the same protocol as detailed for BoNT / AL chain protease in Example 1 was applied. However, the protein was purified by washing with 20 column volumes of 0.1 M Tris pH 8.0 and eluting with 0.1 M Tris pH 8.0 containing 10 mM desthiobiotin on Strep-Tactin agarose beads (IBA Lifesciences, Proteins eluted from Ni2+-nitrilotriacetic acid agarose beads were further purified on a HPLC-MS / ...

[0496] Radiolabeled hSNAP-23 was then produced by in vitro transcription / translation using pS3-hSNAP-23His6, T7-coupled TNT reticulocyte lysate system (Promega), and [35S]methionine (370 KBq / μl, >37 TBq / mmol; Hartmann Analytic, Braunschweig, Germany) according to the manufacturer's instructions.

[0497] The hSNAP-23 cell-free cleavage assay consisted of a final concentration of 20 micromolar recombinant hSNAP-23 plus 1 μl of the transcription / translation mixture of [35S]methionine-labeled hSNAP-23, and each modified or wild-type BoNT / AL chain at a final concentration of 1 micromolar or 10 nanomolar in a total volume of 10 μl toxin assay buffer, incubated at 37°C for 60 minutes. The reaction was terminated by adding an equal volume of double concentrated sample buffer [120 mM Tris-HCl (pH 6.75), 10% (v / v) β-mercaptoethanol, 4% (w / v) SDS, 20% (w / v) glycerol, 0.014% (w / v) bromophenol blue]. After incubation at 37°C for 30 minutes, each sample was analyzed by SDS-PAGE using 15% Tris-glycine gels (acrylamide / bisacrylamide ratio: 73.5:1).

[0498] The gel was dried and the radiolabeled proteins were visualized using a FLA-9000 phosphorimager (Fuji Photo Film, Co., Ltd., Tokyo, Japan). Quantification of radiolabeled proteins and their cleavage products was performed using Multigauge 3.2 software (Fuji Photo Film). To determine the enzymatic kinetic parameters of the wild-type BoNT / AL chain and its mutants, hSNAP-23 produced in E. coli was used with substrate concentrations between 5 and 100 μM. Each different substrate concentration was imparted by adding 1 μl of radiolabeled hSNAP-23 produced by in vitro transcription / translation. Incubation was performed in a final volume of 25 μl toxin assay buffer. After incubation at 37°C for 2 and 4 minutes, a 10 μl aliquot was taken and the enzymatic reaction was terminated by mixing with 10 μl of pre-cooled double concentrated SDS-PAGE sample buffer. The cleavage percentage was determined from the turnover rate of the radiolabeled substrate described in detail above and used to calculate the initial rate of substrate hydrolysis. Km, Kcat and Vmax values ​​were calculated by nonlinear regression using the GraphPad Prism 4.03 program (GraphPad Software Inc., San Diego, USA).

[0499] The resulting data are shown in FIG1 .

[0500] Example 3 - hSNAP-25 Cell-free Cleavage Assay

[0501] The hSNAP-25 (SEQ ID NO: 3) plasmid (pBN10) for E. coli expression has been described in Binz et al. (J Biol Chem., 1994; 269: 1617-20). The codon for the carboxyl-terminal glycine 206 was followed by DNA encoding the amino acid sequence VPPTPGHHHHHH (SEQ ID NO: 7). The plasmid pSNAP-25His6 for in vitro transcription / translation was subsequently generated by subcloning the EcoRI-SalI fragment from pBN10 into correspondingly cut pSP73 (Promega, Mannheim, Germany).

[0502] For protein production and purification of SNAP-25, pBN10 was transfected into E. coli strain M15pREP4 (Qiagen, Hilden, Germany) and the same protocol as detailed in Example 1 for the BoNT / AL chain protease was applied.

[0503] Radiolabeled SNAP-25 was then produced by in vitro transcription / translation using pSNAP-25His6, SP6-coupled TNT reticulocyte lysate system (Promega) and [35S]methionine (370 KBq / μl, >37 TBq / mmol; Hartmann Analytic, Braunschweig, Germany) according to the manufacturer's instructions.

[0504] The hSNAP25 cleavage assay was performed exactly as described in Example 2 for hSNAP-23.

[0505] The resulting data are shown in FIG1 .

[0506] Example 4 - LH comprising a modified light chain A (BoNT / A LC) of the present invention N Preparation of domains

[0507] This example describes a translocation LH containing a modified light chain A (BoNT / A LC) of the present invention that exhibits hSNAP23 cleavage activity. N By adding appropriate targeting moieties, this type of LH N The domains can be used to create a family of TSI delivery vectors.

[0508] Briefly, a BoNT / ALC cloning vector was first constructed for each BoNT / ALC mutant of the present invention by chemically synthesizing DNA (GeneArt, ThermoFisher) encoding the mutant BoNT / ALC, optimized for expression in E. coli, and subcloned into the pCR 4 vector (Invitrogen). N The codon-optimized DNA of the / A domain (corresponding to amino acid residues 449-872 of SEQ ID NO: 8, UniprotKB accession number A5HZZ9) was subcloned into a standard vector, such as pCR 4 vector (Invitrogen), and BoNT / AH was similarly constructed. N The codon-optimized DNA encoding the linker was chemically synthesized and subcloned into the standard vector pCR 4 vector (Invitrogen) to further construct the LH N Specifically, the LH suitable for the BoNT / A serotype was used. N Linker VRGIITSKTKSLDKGYNKALNDL (SEQ ID NO: 9) (which is present in the LC and H N The interdomain polypeptide region between the cysteines of the disulfide bridges between the domains) constructs the LH N Linker vector. Can generate alternative LH N Linker constructs: Indeed, as is known to the skilled practitioner, in order to create a specific protease cleavage site, the natural susceptibility to proteolysis by the LysC protease can be used, or an enterokinase activation site (e.g. DDDDK, SEQ ID NO: 10) can be inserted into the activation loop to generate a sequence such as VDGIITSKTKSDDDDKNKALNLQ (SEQ ID NO: 11), or a protease site of any other protease known in the art, such as PreScision, Factor Xa, thrombin, TEV protease, etc. can be inserted into the activation loop.

[0509] LH was then assembled by cloning the following DNA into a modified pET expression vector (Novagen) in 2 major steps: N domain, wherein the DNA is a DNA encoding each modified BoNT / ALC of the present invention in the presence of a DNA encoding LH N The DNA encoding H N / DNA upstream of the A domain.

[0510] Example 5 - Preparation of TSI delivery vectors of the present invention that bind to non-neuronal cells

[0511] This example describes the process of introducing an LH comprising the modified light chain A of the invention described in Example 2 above. N The TSI delivery vector is constructed by adding a suitable targeting moiety (herein, human GHRP) to each C-terminus of the structural domain. N Flexible linkers were introduced between domains.

[0512] Briefly, the linker-hGHRP cloning vector was constructed by chemically synthesizing codon-optimized DNA encoding a flexible linker fused in-frame to the hGHRP targeting moiety and subcloning into the pCR 4 vector (Invitrogen).

[0513] The DNA encoding the linker-hGHRP was then cloned into a 50 μg / ml PCR product containing the LH N The TSI constructs were assembled in each pET expression vector for the LH domain in such a way that the linker-hGHRP was fused in frame to each LH N C-terminal end of the domain.

[0514] For protein expression of each TSI vector, 100 ml of modified Terrific Broth (TB) medium containing 0.2% glucosamine and 30 μg / ml kanamycin in a 250 ml shake flask was incubated with a single bacterial colony (E. coli BL21 (DE3)) transfected with TSI. Each culture was grown at 37°C, 225 rpm for 16 hours; 10 ml of the overnight culture was then used to inoculate 1 L of modified TB containing 0.2% glucosamine and 30 μg / ml kanamycin in a 2 L shake flask. The resulting cultures were then grown at 37°C until the OD600nm reached approximately 0.5, at which time the temperature was reduced to 16°C. After 1 hour, each culture was induced with 1 mM IPTG and further grown at 16°C for 16 hours. The bacteria were collected by centrifugation and frozen overnight at -20°C.

[0515] Subsequent purification of each TSI expressed was performed as follows.

[0516] The bacteria were thawed and the cell pellet was sonicated to lyse the cells. After centrifugation, the supernatant was loaded onto a 0.1M NiSO4 charged chelating column balanced with 50mM HEPES pH 7.2 200mM NaCl. The column was washed with a buffer containing 40-100mM imidazole (step gradient) to elute non-binding proteins, and the TSI protein was eluted with a buffer containing 200mM imidazole. The fraction containing the target protein (TSI) was then dialyzed against a buffer containing 50mM HEPES pH 7.2 200mM NaCl. The protease (herein LysC) was then added to 1mg of purified TSI in an appropriate amount to activate it (i.e., so that TSI forms a double chain, is able to bind GHRP, translocates the light chain into the cytoplasm, and catalyzes the cleavage of hSNAP23). The resulting mixture was then further purified by loading it onto a 0.1M NiSO4 charged chelating column equilibrated with 50mM HEPES pH 7.2 200mM NaCl. The column was first washed with 50mM HEPES pH 7.2 200mM NaCl, then washed with a buffer containing 40-100mM imidazole to elute non-specifically bound proteins, and then washed with a buffer containing 200mM imidazole to elute activated TSI. The fraction containing the activated protein of interest (TSI) was then dialyzed against a buffer containing 50mM HEPES pH 7.2 150mM NaCl. The dialyzed protein was then concentrated to about 2mg / ml, aliquoted and finally frozen at -80°C.

[0517] project

[0518] 1. A modified botulinum neurotoxin A (BoNT / A) L chain protease that cleaves human SNAP-23 (hSNAP-23) and has a modified amino acid sequence relative to the wild-type BoNT / AL chain (SEQ ID NO: 1), comprising:

[0519] a) alteration of at least one amino acid residue within the first BoNT / AL chain protease binding pocket located at the P182 / D178 binding site for binding to hSNAP-23;

[0520] b) wherein the first BoNT / AL chain protease binding pocket is defined by amino acid residues E148, T307, A308, and Y312 of the wild-type BoNT / AL chain (SEQ ID NO: 1); and

[0521] c) wherein the at least one amino acid residue change comprises:

[0522] i. an amino acid residue selected from the group consisting of asparagine and tyrosine at the position on the modified L chain protease amino acid sequence corresponding to amino acid residue E148 of the wild-type BoNT / AL chain (SEQ ID NO: 1); and / or

[0523] ii. an amino acid residue selected from the group consisting of phenylalanine, isoleucine, and leucine at the position on the modified L chain protease amino acid sequence corresponding to amino acid residue T307 of the wild-type BoNT / AL chain (SEQ ID NO: 1); and / or

[0524] iii. an amino acid residue selected from the group consisting of proline, asparagine, threonine, and isoleucine at the position on the modified L chain protease amino acid sequence corresponding to amino acid residue A308 of the wild-type BoNT / AL chain (SEQ ID NO: 1); and / or

[0525] iv. an amino acid residue selected from the group consisting of lysine, valine, methionine, and leucine at the position on the modified L chain protease amino acid sequence corresponding to amino acid residue Y312 of the wild-type BoNT / AL chain (SEQ ID NO: 1).

[0526] 2. The modified BoNT / AL chain protease of claim 1, further comprising:

[0527] a) changes in amino acid residues located within the second BoNT / AL chain protease binding pocket of the R186 binding site for binding to hSNAP-23;

[0528] b) wherein the second BoNT / AL chain protease binding pocket is defined as amino acid residue S143 of the wild-type BoNT / AL chain (SEQ ID NO: 1); and

[0529] c) wherein the amino acid residue changes comprise:

[0530] i. An amino acid residue selected from the group consisting of glutamine, glutamic acid, and aspartic acid at the position on the modified L chain protease amino acid sequence corresponding to amino acid residue S143 of the wild-type BoNT / AL chain (SEQ ID NO: 1).

[0531] 3. The modified BoNT / AL chain protease of item 1 or 2, further comprising:

[0532] a) alteration of at least one amino acid residue located within the third BoNT / AL chain protease binding pocket located within the K185 binding site for binding to hSNAP-23;

[0533] b) wherein the third BoNT / AL chain protease binding pocket is defined by amino acid residues V304 and G305 of the wild-type BoNT / AL chain (SEQ ID NO: 1); and

[0534] c) wherein the at least one amino acid residue change comprises:

[0535] i. an amino acid residue selected from glutamic acid and aspartic acid at the position on the modified L chain protease amino acid sequence corresponding to amino acid residue V304 of the wild-type BoNT / AL chain (SEQ ID NO: 1); and / or

[0536] ii. an amino acid residue selected from glutamic acid and aspartic acid at the position on the modified L chain protease amino acid sequence corresponding to amino acid residue G305 of the wild-type BoNT / AL chain (SEQ ID NO: 1).

[0537] 4. The modified BoNT / AL chain protease of any of the preceding items, further comprising:

[0538] a) changes in amino acid residues located within the fourth BoNT / AL chain protease binding pocket located at the D189 / D192 binding site for binding to hSNAP-23;

[0539] b) wherein the fourth BoNT / AL chain protease binding pocket is defined as amino acid residue Q29 of the wild-type BoNT / AL chain (SEQ ID NO: 1);

[0540] c) wherein the amino acid residue changes comprise:

[0541] i. An amino acid residue selected from alanine at the position on the modified L chain protease amino acid sequence corresponding to amino acid residue Q29 of the wild-type BoNT / AL chain (SEQ ID NO: 1).

[0542] 5. The modified BoNT / AL chain protease of any of the preceding items, further comprising:

[0543] a) alteration of at least one amino acid residue located within the fifth BoNT / AL chain protease binding pocket located within the K206 binding site for binding to hSNAP-23;

[0544] b) wherein the fifth BoNT / AL chain protease binding pocket is defined by amino acid residues Y251, L256, V258, L367, and F369 of the wild-type BoNT / AL chain (SEQ ID NO: 1);

[0545] c) wherein the at least one amino acid residue change comprises:

[0546] i. an amino acid residue selected from glutamic acid and aspartic acid at the position on the modified L chain protease amino acid sequence corresponding to amino acid residue Y251 of the wild-type BoNT / AL chain (SEQ ID NO: 1); and / or

[0547] ii. an amino acid residue selected from the group consisting of glutamic acid, aspartic acid, glutamine, glycine, alanine, and arginine at the position on the modified L chain protease amino acid sequence corresponding to amino acid residue L256 of the wild-type BoNT / AL chain (SEQ ID NO: 1); and / or

[0548] iii. an amino acid residue selected from the group consisting of serine, alanine, proline, leucine, and glutamic acid at the position on the modified L chain protease amino acid sequence corresponding to amino acid residue V258 of the wild-type BoNT / AL chain (SEQ ID NO: 1); and / or

[0549] iv. an amino acid residue selected from alanine and glycine at the position on the modified L chain protease amino acid sequence corresponding to amino acid residue L367 of the wild-type BoNT / AL chain (SEQ ID NO: 1); and / or

[0550] v. an amino acid residue selected from the group consisting of glycine, serine, and leucine at the position on the modified L chain protease amino acid sequence corresponding to amino acid residue F369 of the wild-type BoNT / AL chain (SEQ ID NO: 1).

[0551] 6. The modified BoNT / AL chain protease of any of the preceding items, further comprising:

[0552] a) changes in amino acid residues located within the sixth BoNT / AL chain protease binding pocket located at the I198 binding site for binding to hSNAP-23;

[0553] b) wherein the sixth BoNT / AL chain protease binding pocket is defined as amino acid residue K166 of the wild-type BoNT / AL chain (SEQ ID NO: 1); and

[0554] c) wherein the amino acid residue changes comprise:

[0555] i. An amino acid residue selected from the group consisting of valine, phenylalanine, leucine, and isoleucine at the position on the modified L chain protease amino acid sequence corresponding to amino acid residue K166 of the wild-type BoNT / AL chain (SEQ ID NO: 1).

[0556] 7. The modified BoNT / AL chain protease of any of the preceding items, further comprising:

[0557] a) changes in amino acid residues located within the seventh BoNT / AL chain protease binding pocket of the D210 binding site for binding to hSNAP-23;

[0558] b) wherein the seventh BoNT / AL chain protease binding pocket is defined as amino acid residue S254 of the wild-type BoNT / AL chain (SEQ ID NO: 1); and

[0559] c) wherein the amino acid residue changes comprise:

[0560] i. An amino acid residue selected from alanine at the position on the modified L chain protease amino acid sequence corresponding to amino acid residue S254 of the wild-type BoNT / AL chain (SEQ ID NO: 1).

[0561] 8. The modified BoNT / AL chain protease of any of the preceding items, further comprising:

[0562] a) changes in amino acid residues located within the eighth BoNT / AL chain protease binding pocket of the D168 binding site for binding to hSNAP-23;

[0563] b) wherein the eighth BoNT / AL chain protease binding pocket is defined as amino acid residue K340 of the wild-type BoNT / AL chain (SEQ ID NO: 1); and

[0564] c) wherein the amino acid residue changes comprise:

[0565] i. An amino acid residue selected from histidine at the position on the modified L chain protease amino acid sequence corresponding to amino acid residue K340 of the wild-type BoNT / AL chain (SEQ ID NO: 1).

[0566] 9. A modified botulinum neurotoxin A (BoNT / A) L chain protease that cleaves human SNAP-23 (hSNAP-23) and has a modified amino acid sequence relative to the wild-type BoNT / AL chain (SEQ ID NO: 1), comprising:

[0567] a) changes in amino acid residues located within the fourth BoNT / AL chain protease binding pocket located at the D189 / D192 binding site for binding to hSNAP-23;

[0568] b) wherein the fourth BoNT / AL chain protease binding pocket is defined as amino acid residue Q29 of the wild-type BoNT / AL chain (SEQ ID NO: 1); and

[0569] c) wherein the amino acid residue changes comprise:

[0570] i. An amino acid residue selected from alanine at the position on the modified L chain protease amino acid sequence corresponding to amino acid residue Q29 of the wild-type BoNT / AL chain (SEQ ID NO: 1).

[0571] 10. A modified botulinum neurotoxin A (BoNT / A) L chain protease that cleaves human SNAP-23 (hSNAP-23) and has a modified amino acid sequence relative to the wild-type BoNT / AL chain (SEQ ID NO: 1), comprising:

[0572] a) changes in amino acid residues located within the sixth BoNT / AL chain protease binding pocket located at the I198 binding site for binding to hSNAP-23;

[0573] b) wherein the sixth BoNT / AL chain protease binding pocket is defined as amino acid residue K166 of the wild-type BoNT / AL chain (SEQ ID NO: 1); and

[0574] c) wherein the amino acid residue changes comprise:

[0575] i. An amino acid residue selected from the group consisting of valine, phenylalanine, leucine, and isoleucine at the position on the modified L chain protease amino acid sequence corresponding to amino acid residue K166 of the wild-type BoNT / AL chain (SEQ ID NO: 1).

[0576] 11. A modified botulinum neurotoxin A (BoNT / A) L chain protease that cleaves human SNAP-23 (hSNAP-23) and has a modified amino acid sequence relative to the wild-type BoNT / AL chain (SEQ ID NO: 1), comprising:

[0577] a) alteration of at least one amino acid residue located within the fifth BoNT / AL chain protease binding pocket located within the K206 binding site for binding to hSNAP-23;

[0578] b) wherein the fifth BoNT / AL chain protease binding pocket is defined by amino acid residues Y251, L256, V258, L367, and F369 of the wild-type BoNT / AL chain (SEQ ID NO: 1); and

[0579] c) wherein the at least one amino acid residue change comprises:

[0580] i. an amino acid residue selected from glutamic acid and aspartic acid at the position on the modified L chain protease amino acid sequence corresponding to amino acid residue Y251 of the wild-type BoNT / AL chain (SEQ ID NO: 1); and / or

[0581] ii. an amino acid residue selected from the group consisting of aspartic acid, glutamine, glycine, alanine, and arginine at the position on the modified L chain protease amino acid sequence corresponding to amino acid residue L256 of the wild-type BoNT / AL chain (SEQ ID NO: 1); and / or

[0582] iii. an amino acid residue selected from the group consisting of serine, alanine, proline, leucine, and glutamic acid at the position on the modified L chain protease amino acid sequence corresponding to amino acid residue V258 of the wild-type BoNT / AL chain (SEQ ID NO: 1); and / or

[0583] iv. an amino acid residue selected from alanine and glycine at the position on the modified L chain protease amino acid sequence corresponding to amino acid residue L367 of the wild-type BoNT / AL chain (SEQ ID NO: 1); and / or

[0584] v. an amino acid residue selected from the group consisting of glycine, serine, and leucine at the position on the modified L chain protease amino acid sequence corresponding to amino acid residue F369 of the wild-type BoNT / AL chain (SEQ ID NO: 1).

[0585] 12. A modified botulinum neurotoxin A (BoNT / A) L chain protease that cleaves human SNAP-23 (hSNAP-23) and has a modified amino acid sequence relative to the wild-type BoNT / AL chain (SEQ ID NO: 1), comprising:

[0586] a) changes in amino acid residues located within the seventh BoNT / AL chain protease binding pocket of the D210 binding site for binding to hSNAP-23;

[0587] b) wherein the seventh BoNT / AL chain protease binding pocket is defined as amino acid residue S254 of the wild-type BoNT / AL chain (SEQ ID NO: 1); and

[0588] c) wherein the amino acid residue changes comprise:

[0589] i. An amino acid residue selected from alanine at the position on the modified L chain protease amino acid sequence corresponding to amino acid residue S254 of the wild-type BoNT / AL chain (SEQ ID NO: 1).

[0590] 13. A modified botulinum neurotoxin A (BoNT / A) L chain protease that cleaves human SNAP-23 (hSNAP-23) and has a modified amino acid sequence relative to the wild-type BoNT / AL chain (SEQ ID NO: 1), comprising:

[0591] a) changes in amino acid residues located within the eighth BoNT / AL chain protease binding pocket of the D168 binding site for binding to hSNAP-23;

[0592] b) wherein the eighth BoNT / AL chain protease binding pocket is defined as amino acid residue K340 of the wild-type BoNT / AL chain (SEQ ID NO: 1); and

[0593] c) wherein the amino acid residue changes comprise:

[0594] i. An amino acid residue selected from histidine at the position on the modified L chain protease amino acid sequence corresponding to amino acid residue K340 of the wild-type BoNT / AL chain (SEQ ID NO: 1).

[0595] 14. The modified botulinum neurotoxin A (BoNT / A) L chain protease according to any one of items 9 to 13, further comprising at least one amino acid residue change positioned within a different BoNT / AL chain protease binding pocket, wherein the amino acid residue change and the other BoNT / AL chain protease binding pocket are defined as the technical features of any one of items 1 to 13.

[0596] 15. A nucleic acid construct comprising or consisting of a nucleic acid sequence encoding a modified BoNT / AL chain protease as described in any preceding item.

[0597] 16. A delivery vehicle comprising:

[0598] a) the modified BoNT / AL chain protease of any one of items 1 to 14, or the nucleic acid construct of item 15; and

[0599] b) elements for delivering said modified BoNT / AL chain protease or said nucleic acid construct into target cells, preferably into non-neuronal target cells.

[0600] 17. The delivery vector of item 16, wherein element b) for delivering the modified BoNT / AL chain protease to target cells comprises:

[0601] i) a targeting moiety that enables the delivery vehicle to bind to a target cell; and

[0602] ii) a translocation peptide that translocates the modified BoNT / AL chain protease or nucleic acid construct into a target cell, preferably into a non-neuronal target cell.

[0603] 18. A method for cleaving hSNAP-23, comprising contacting hSNAP-23 with the (BoNT / A) L chain protease of any one of items 1 to 14, or with the nucleic acid construct of item 15, or with the delivery vector of item 16 or 17.

[0604] 19. The (BoNT / A) L chain protease according to any one of items 1 to 14, or the nucleic acid construct of item 15, or the delivery vector of item 16 or 17, for use in the method of item 18.

Claims

1. A modified botulinum neurotoxin A (BoNT / A) L chain protease that exhibits increased cleavage of human SNAP-23 (hSNAP-23) relative to the wild-type BoNT / AL chain (SEQ ID NO: 1) and has a modified amino acid sequence relative to the wild-type BoNT / AL chain (SEQ ID NO: 1), comprising: a) alteration of at least one amino acid residue within the third BoNT / AL chain protease binding pocket located in the 1198 binding site for binding to hSNAP-23; and b) wherein the third BoNT / AL chain protease binding pocket is defined as amino acid residue K166 of the wild-type BoNT / AL chain (SEQ ID NO: 1); c) wherein the at least one amino acid residue change comprises: The amino acid phenylalanine at the position on the modified L chain protease amino acid sequence corresponding to amino acid residue K166 of the wild-type BoNT / AL chain (SEQ ID NO: 1).

2. The modified BoNT / AL chain protease of claim 1, further comprising: a) alteration of at least one amino acid residue within the second BoNT / AL chain protease binding pocket located in the D189 / D192 binding site for binding to hSNAP-23; b) wherein the second BoNT / AL chain protease binding pocket is defined as amino acid residue Q29 of the wild-type BoNT / AL chain (SEQ ID NO: 1); and c) wherein the amino acid residue changes comprise: The amino acid residue at the position on the modified L chain protease amino acid sequence corresponding to amino acid residue Q29 of the wild-type BoNT / AL chain (SEQ ID NO: 1) is selected from alanine.

3. The modified BoNT / AL chain protease of any of the preceding claims, further comprising: a) alteration of at least one amino acid residue located within the fourth BoNT / AL chain protease binding pocket located within the K185 binding site for binding to hSNAP-23; b) wherein the fourth BoNT / AL chain protease binding pocket is defined as amino acid residue G305 of the wild-type BoNT / AL chain (SEQ ID NO: 1); and c) wherein the at least one amino acid residue change comprises: The position on the modified L chain protease amino acid sequence corresponding to amino acid residue G305 of the wild-type BoNT / AL chain (SEQ ID NO: 1) is an amino acid residue selected from glutamic acid and aspartic acid.

4. The modified BoNT / AL chain protease of any of the preceding claims, further comprising: a) alteration of at least one amino acid residue located within the fifth BoNT / AL chain protease binding pocket of the R186 binding site for binding to hSNAP-23; b) wherein the fifth BoNT / AL chain protease binding pocket is defined as amino acid residue S143 of the wild-type BoNT / AL chain (SEQ ID NO: 1); and c) wherein the amino acid residue changes comprise: The position on the modified L chain protease amino acid sequence corresponding to amino acid residue S143 of the wild-type BoNT / AL chain (SEQ ID NO: 1) is an amino acid residue selected from the group consisting of glutamine, glutamic acid, and aspartic acid.

5. The modified BoNT / AL chain protease of any of the preceding claims, further comprising: a) alteration of at least one amino acid residue located within the sixth BoNT / AL chain protease binding pocket located within the K206 binding site for binding to hSNAP-23; b) wherein the sixth BoNT / AL chain protease binding pocket is defined as amino acid residue Y251 of the wild-type BoNT / AL chain (SEQ ID NO: 1); and c) wherein the at least one amino acid residue change comprises: The position on the modified L chain protease amino acid sequence corresponding to amino acid residue Y251 of the wild-type BoNT / AL chain (SEQ ID NO: 1) is an amino acid residue selected from glutamic acid and aspartic acid.

6. The modified BoNT / AL chain protease of any of the preceding claims, further comprising: a) alteration of at least one amino acid residue located within the seventh BoNT / AL chain protease binding pocket of the D210 binding site for binding to hSNAP-23; b) wherein the seventh BoNT / AL chain protease binding pocket is defined as amino acid residue S254 of the wild-type BoNT / AL chain (SEQ ID NO: 1); and c) wherein the amino acid residue changes comprise: i. An amino acid residue alanine at the position on the modified L chain protease amino acid sequence corresponding to amino acid residue S254 of the wild-type BoNT / AL chain (SEQ ID NO: 1).

7. A vector comprising a nucleic acid construct comprising or consisting of a nucleic acid sequence encoding the modified BoNT / AL chain protease of any preceding claim.

8. A delivery vehicle comprising: a) the modified BoNT / AL chain protease of any one of claims 1 to 6, or the vector of claim 7; and b) an element for delivering the modified BoNT / AL chain protease or the vector into a target cell, wherein the element b) for delivering the modified BoNT / AL chain protease to a target cell comprises: i) a targeting moiety that enables the delivery vehicle to bind to a target cell; and ii) a translocation peptide that translocates the modified BoNT / AL chain protease or nucleic acid construct into the target cell.

9. The delivery vehicle of claim 8, wherein the target cell is a non-neuronal target cell.

10. An in vitro method for cleaving hSNAP-23, comprising contacting hSNAP-23 with the (BoNT / A) L chain protease of any one of claims 1 to 6 or with the delivery vector of claim 8 or 9, wherein the delivery vector comprises the modified BoNT / AL chain protease of any one of claims 1 to 6.

11. Use of the (BoNT / A) L chain protease of any one of claims 1 to 6 or the delivery vector of claim 8 or 9 for the preparation of a medicament for treating a secretory disease, wherein the delivery vector comprises the modified BoNT / AL chain protease of any one of claims 1 to 6.

Citation Information

Patent Citations

  • Post-translational modifications and Clostridial neurotoxins

    US7223577B2

  • Botulinum toxin derivatives able to modify peripheral sensory afferent functions

    WO1996033273A1

  • Recombinant toxin fragments

    WO1998007864A1

  • Treatment of mucus hypersecretion

    WO2000010598A2

  • Inhibition of secretion from non-neuronal cells

    WO2001021213A2